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Abstract 
RBM5 is a tumour suppressor gene with substantially decreased expression in most lung cancers, 
especially in smokers, that may result from gene deletion. The objective of this study was to 
determine if significantly decreased levels of RBM5 expression in the lung cancers of smokers 
was related to RBM5 deletion. Using DNA from patient lung tissue, RBM5 gene copy number 
was quantified by quantitative polymerase chain reaction. Although deletions were detected in 
the lung specimens, RBM5 gene copy number was not significantly decreased in lung tumours. 
RBM5 deletions were detected in the non-tumour DNA of smokers, but not in the never-smokers, 
indicating that RBM5 gene deletion might be related to smoking. In conclusion, it appeared as 
though RBM5 was downregulated by more than one mechanism, which included gene deletion. 
Further analyses must be carried out to examine other mechanisms by which RBM5 is 
downregulated. 
 
Keywords 
RBM5, non-small cell lung cancer, small cell lung cancer, gene copy number, gene deletion, 
expression, tobacco smoke exposure, smokers, never-smokers 
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Chapter 1  
1 Introduction 
1.1 RNA Binding Proteins 
RNA binding proteins (RBPs) are regulatory elements within the cell that play an important role 
in the post-transcriptional processing of RNA 1,2. It is estimated that the human genome codes for 
over 500 RBPs, each with essential functions in RNA metabolism in both the nucleus and the 
cytoplasm 3,4. In order for a protein to be considered a RBP, it must contain at least one RNA 
binding domain 1. The most commonly observed RNA binding domains include RNA 
Recognition Motif (RRM) domains, K Homology (KH) domains and Zinc Finger (ZnF) domains 
1,4. These domains can undergo a level of post-translational modification (PTM), usually through 
acetylation or phosphorylation 5,6. This mechanism of RBP regulation suggests that RBPs 
function as a part of complex metabolic and signalling networks 6. Using their functional 
domains, RBPs can bind with their RNA target, forming a ribonucleoprotein (RNP) complex 7. 
Generally, RBPs will interact with the untranslated regions of RNA transcripts, but they have 
also been documented to interact with coding regions and even non-protein-coding RNA 4,5. 
Once bound to their target RNA, RBPs regulate many aspects of RNA metabolism including 
alternative splicing, polyadenylation, mRNA stabilization, editing and repair, nucleocytoplasmic 
transport, translation and RNA degradation 1,4,7. Due to the vast functions of RBPs, and the sheer 
number of RBPs within a given cell, these proteins are critical for controlling gene expression at 
the post-transcriptional level. 
Dysregulation of RBPs is linked to various diseases, including cancer. RBPs can exhibit a 
cancerous phenotype following mutations or alterations in expression 8. Mutations in RBPs, 
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including binding site mutations, can lead to altered binding affinities and changes in subcellular 
localization 4. RBPs harbouring non-silent mutations in their RNA binding domain either can 
have a reduced ability to bind to RNA targets, or, have an enhanced ability to bind to RNA 
targets 9. Both reduced binding ability and increased binding stability between RBPs and their 
RNA target can lead to the downregulation of target transcripts. Chromosomal translocations of 
RBPs have also been reported in cancer, leading to fusion proteins that display oncogenic 
properties 5.  
In regards to altered RBP expression, both increased and decreased expression of RBPs have 
been observed 5. Overexpression of RBPs, through processes such as gene amplification, 
demonstrates enhanced RBP activity and abnormal function 5,8. Conversely, decreased 
expression of RBPs hinders proper functioning 5. Considering the multitude of functions that 
RBPs possess, any abnormalities in RBP function or expression can lead to defects in cell 
differentiation, cell division, integrity checkpoints and response to stimuli 4,5. Currently, it is not 
understood whether mutations or changes in expression of RBPs are involved in cancer 
initiation, or are a by-product of cancer, meaning that further investigation of RBPs in cancer is 
necessary. 
1.2 RBM5 
RNA Binding Motif 5 (RBM5) is a RNA binding protein that maps to 3p21.3, and is considered 
a putative tumour suppressor gene (TSG) 10. It was first cloned in 1996 as LUCA-15, but has 
also been cloned as H37,  RBM5 and LUCA15 11-14. The RBM5 gene extends approximately 30 
kilobases (kb). Full-length RBM5 mRNA consists of over 2500 base pairs (bp), containing 25 
exons, ranging between 61 bp and 627 bp 13,15. RBM5 mRNA also has alternative splice variants, 
but for the purposes of this study, we will be focusing solely on full-length RBM5. The RBM5 
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protein consists of 815 amino acids and has a calculated molecular weight of 90 kilo Daltons 
(kDa) 13. Using the most accurate RBM5 antibody, the RBM5 protein is observed on Western 
blots as ~113 kDa, suggesting that the RBM5 protein is post-translationally modified 16. In fact, 
RBM5 is a known phosphoprotein, with the dephosphorylated state being associated with 
apoptosis 17. Post-translational modification of the RBM5 protein may, therefore, play an 
important role in RBM5 function. 
1.2.1 RBM5 Function 
RBM5 regulates the cell cycle and modulates apoptosis through the alternative splicing of pre-
mRNA in the nucleus. It was reported that the downregulation of RBM5 affects transcript levels 
of 35 transcripts involved in cell proliferation and apoptosis 18. The two RRM domains on the 
RBM5 protein have been shown to bind to pre-mRNA, resulting in the alternative splicing of 
various transcripts 19. Full-length RBM5 has a role in the alternative splicing of apoptosis-
associated transcripts such as Caspase 2, Fas and c-FLIP 20-22. RBM5 has been demonstrated to 
promote apoptosis through a number of pathways including Fas, TNF-α, TRAIL and p53 23,24. 
RBM5-mediated apoptosis was correlated with an increase in expression of a number of pro-
apoptotic factors such as BAX, mitochondrial cytochrome c in the cytosol, and Caspases 3 and 9, 
as well as a decrease in the expression of anti-apoptotic Bcl-2 and Bcl-x 25-27. With regards to 
cell cycle regulation, RBM5 was shown to arrest cells in G1 phase, thereby promoting apoptosis 
27,28. 
A number of studies have examined the function of RBM5 in vitro, especially using the human 
lung adenocarcinoma A549 cell line. RBM5 overexpression suppressed growth in A549 cells, 
along with other cell lines, including HT108, RBM5-null MCF-7, H1299 cells, PC-3 cells and 
mouse A9 cells 14,27-31. In two of those studies, overexpression of RBM5 in the A549 cell line 
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also demonstrated a higher proportion of cells arrested in the G1 phase, leading to an increase in 
apoptosis 27,28. This finding was also confirmed in the CEM-C7 cell line 27,28. Overexpression of 
RBM5 in A549 also resulted in reduced expression of EGFR mRNA and protein expression, 
thereby preventing EGFR-mediated cell proliferation 32. Furthermore, RBM5 overexpression in 
A549 cells was also associated with decreased expression of Cyclin A, a protein responsible for 
cell cycle progression, and with decreased expression of phosphorylated RB, which, while 
phosphorylated, is considered inert and allows for cell cycle progression 27. A549 cells treated 
with cigarette smoke extract (CSE) demonstrated decreased RBM5 expression levels and 
increased Wnt and β-catenin protein expression levels, suggesting that RBM5 may also regulate 
the Wnt pathway 33. To support this finding, RBM5 knockdown (KD) in A549 cells was 
associated with increased β-catenin, and this observation was confirmed in other cell lines 
including Calu-6, BEAS-2B, H1299 and MCF-10A 34. In regards to treatment outcomes, 
overexpression of RBM5 in A549 cells led to reduced resistance to the chemotherapeutic agent, 
Cisplatin 35. When A549 cells overexpressing RBM5 were injected intraperitoneally into 
immunocompromised mice, tumours exhibited retarded growth in vivo, further demonstrating the 
role of RBM5 as a putative tumour suppressor 27. From the collective work completed in the 
A549 cell model, it can be concluded that RBM5 plays an important role in downregulating cell 
cycle progression, leading to growth arrest and apoptosis. 
RBM5 studies have also been completed in the human BEAS-2B normal bronchial epithelial cell 
line. When RBM5 was overexpressed in CSE-transformed cells, proliferation, invasion and 
migration was inhibited 36. An increase in G1/S arrest and apoptosis was observed in the CSE-
transformed cells overexpressing RBM5, further confirming that the growth inhibitory properties 
of RBM5 are completed through cell cycle arrest and the induction of apoptosis, as was seen in 
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A549 studies mentioned previously 36. To expand on this finding, RBM5 overexpression was 
related to an increase in mRNA transcripts that regulate apoptosis, including pro-apoptotic 
Caspases 9 and 3 and BAX, and was also related to a decrease in mRNA expression of anti-
apoptotic Bcl-2 36. Overexpression of RBM5 in these cells was also related to reduced mRNA 
transcript levels of CDK4, CDK6, Cyclin D1 and Cyclin A, which are all involved in cell cycle 
progression, and increased transcript levels of p53 and p21, further promoting apoptosis 36. In 
response to cell invasion and migration, increased RBM5 overexpression was associated with a 
significant decrease in VEGF, HIF-α, MMP2 and MMP9 mRNA levels, all of which are 
involved in metastasis 36. Supporting the role of RBM5 as a tumour suppressor in vivo¸ it was 
also demonstrated that tumour growth was inhibited in xenografts overexpressing RBM5 in nude 
mice, similar to what was seen in similar A549 studies 36. This study in CSE-transformed BEAS-
2B cells highlights the importance of RBM5 expression during the transformation of normal 
bronchial epithelial cells to a cancerous phenotype, especially in tobacco smoke-associated lung 
cancers. 
One recent study examined the effect of re-introducing RBM5 expression at varying levels into 
an RBM5-null cell line, GLC20. Through RNA sequencing, it was determined that 12% of the 
transcriptome was differentially expressed when RBM5 was introduced at low levels, and 18% 
of the transcriptome was differentially expressed when RBM5 was introduced at high levels 16. 
In both low and high RBM5-expressing cell lines, 50% of differentially expressed genes were 
shared between cell lines 16. It was reported that RBM5 expression was important to the 
maintenance of the non-transformed state 16. This phenomenon was completed through the 
regulation of pathways involved in the cell cycle and apoptosis 16. Functional studies were 
completed to confirm that these effects were observed in vitro. Indeed, it was demonstrated that 
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increased RBM5 expression was associated with a decrease in cell proliferation and membrane 
integrity and an increase in apoptosis, especially in the presence of Cisplatin, a chemotherapeutic 
agent commonly used in the treatment of SCLC 16.  
1.2.2 RBM5 Expression 
RBM5 is ubiquitously expressed in all primary tissue. It exists at high levels in tissue such as the 
pancreas, heart and skeletal muscle, and exists at low levels in the liver and lung 29,37-39. For the 
purpose of this study, we will be focusing solely on RBM5 expression in lung cancer. In a subset 
of lung cancers, referred to as non-small cell lung cancer (NSCLC), RBM5 showed reduced 
mRNA expression in 65-82% of NSCLC tumours, compared to adjacent non-tumour tissue 29,40. 
Looking at specific NSCLC subtypes, decreased RBM5 expression occurred in both 
adenocarcinoma (ADC) and squamous cell carcinoma (SqCC), but occurred more frequently in 
SqCC 29. A separate study examining small cell lung cancer (SCLC) RNA found 50% reduction 
in RBM5 expression between non-tumour and tumour RNA, but this was only analyzed in two 
patients 16. At the protein level, RBM5 expression showed downregulation in approximately 70% 
of NSCLC tumours 27,40. Downregulation of the RNA transcript and protein was noted in a 
number of lung cancer studies, illustrating the importance of loss of RBM5 expression in lung 
cancer. Of even greater interest, it was observed that downregulation of RBM5 in lung cancer 
occurs more often in smokers, compared to never-smokers 40. The link between decreased RBM5 
expression and tobacco smoke exposure observed in patients was also demonstrated in vitro, as 
CSE-transformed BEAS-2B cells had reduced expression of RBM5 compared to wild-type 
BEAS-2B cells 36. In addition to the relationship between RBM5 expression and tobacco smoke 
exposure, decreased RBM5 expression was also correlated with metastasis 34,40,41. One study, 
completed in 2003, found that decreased RBM5 mRNA expression was part of a 17-gene 
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signature associated with metastasis in 12 solid tumour types, including lung ADC 41. Two 
separate studies also demonstrated that decreased RBM5 expression was associated with lymph 
node metastasis 34,40. With all of these studies taken as a whole, it appears as though loss of 
RBM5 expression is important for the development of most lung cancers, especially tobacco 
smoke-associated lung cancers, and is also important for lung cancer progression towards a 
metastatic phenotype. 
1.2.3 RBM5 Regulation 
The mechanism responsible for the frequent downregulation of RBM5 in lung cancer has been 
investigated previously, but, currently, the exact mechanism of RBM5 downregulation is 
unknown. One of the first studies, completed in 1999, involved the sequencing of cDNA from 14 
SCLC and two NSCLC cell lines. The purpose of this study was to identify any aberrations in the 
cDNA that would disrupt the structure and functionality of the resultant RBM5 protein, 
promoting lung cancer development. Northern and Southern blot analyses did not detect any 
abnormalities in the RNA or the cDNA of the 16 cell lines 13. Only one mutation was noted in an 
adenocarcinoma cell line, GLCA2, demonstrating a GT transversion at codon 398 13. This 
mutation resulted in an amino acid substitution from a glycine to a valine, which was not likely 
to alter the protein structure and function 13. Mutations in RBM5 cDNA were investigated a 
second time in 2007. In this study, it was hypothesized that RBM5 downregulation in tumours, at 
the RNA and/or protein level, was the result of an inactivating mutation following Knudson’s 
two-hit hypothesis, similar to classic tumour TSGs such as RB and TP53. To examine mutations 
that were of functional relevance, cDNA from 17 NSCLC tumour and non-tumour pairs were 
sequenced. Upon analysis, there were not any protein-altering mutations present in any of the 
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samples, indicating that, once again, mutation was unlikely to be the mechanism of RBM5 
downregulation in lung cancer 42. 
Promoter hypermethylation has also been investigated as a mechanism of RBM5 
downregulation. This type of epigenetic alteration involves the addition of methyl groups to 
cytosine bases at various CpG sites in the promoter region 43. A 949 bp CpG island in the RBM5 
promoter region, containing 69 CpG dinucleotides, was examined in DNA from 11 NSCLC 
tumour and non-tumour pairs, as well as three NSCLC cell lines (A549, H460 and H520) 44. This 
study did not find any evidence of promoter hypermethylation; however, there were 
experimental limitations that could have contributed to this finding. First, only two regions of the 
949 bp CpG island were amplified: a 204 bp region that included the transcription start site and 
14 CpG sites, and a 164 bp region downstream of the transcription start site containing 18 CpG 
sites. The remaining 541 bp and 37 CpG sites were not examined, preventing a complete 
investigation of the RBM5 CpG island of interest. Second, tobacco smoke exposure, which has 
been shown to influence methylation in NSCLC, was not taken into account. Given the 
limitations of this study, promoter hypermethylation cannot be ruled out as a mechanism of 
RBM5 downregulation. 
As mentioned previously, the RBM5 gene resides at the locus 3p21.3. This region frequently 
undergoes loss of heterozygosity (LOH) in 70% of NSCLCs and 95% of SCLCs 45-47. It is one of 
the earliest preneoplastic alterations observed in the lung, and has even been found in normal 
bronchial epithelium of smokers 47. It is, therefore, possible that gene deletion is one of the 
mechanisms by which RBM5 is downregulated in lung cancer, especially in lung cancers 
associated with tobacco smoke exposure. RBM5 gene deletions were first noted in SCLC cell 
lines GLC20, NCI-H740 and NCI-H1450 39. Each of these cell lines demonstrated homozygous  
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deletions in a ~370 kb deletion region within the 3p21.3 locus 39. In this deletion region, the 
RBM5 gene was located proximal to the telomeric breakpoint within the RBM6 gene 39. Another 
study, completed in 2004, examined deletions in the ~370 kb critical deletion region in 23 lung 
cancer cell lines (16 SCLC, four ADC, one SqCC, one large cell carcinoma and one mixed 
NSCLC). This study demonstrated that the RBM5 gene was located distal to the telomeric border 
of the smallest deletion region common to all of the samples examined and, therefore, not 
included in the deletion region 48. This study further examined deletions in all lung cancer cell 
lines by examining copy number of a gene located within the deletion region, GNAI2. 
Homozygous deletions of GNAI2 were detected in only two of the 16 SCLC cell lines, and none 
of the NSCLC cell lines 48. Interestingly, hemizygosity of GNAI2 was detected in 10 of the 23 
lung cancer cell lines (one mixed NSCLC cell line, three ADC cell lines, one SqCC cell line and 
five SCLC cell lines) 48. This finding suggests that loss of the ~370 kb critical deletion region, 
from at least one chromosome, is important to lung cancer. Taking both studies into account, the 
RBM5 gene lies close to the telomeric breakpoint and is sometimes deleted in lung cancer, 
thereby substantiating the possibility that gene deletion is at least one mechanism by which 
RBM5 is downregulated in lung cancer. 
1.3 Tumour Suppressor Genes and Lung Cancer 
TSGs must be downregulated in order for cancer to progress. TSGs regulate various aspects of 
the cell cycle including cell proliferation, DNA repair and apoptosis 49. Direct suppression of 
proliferation is controlled by numerous TSGs throughout the cell cycle in response to stimuli 
signaling for growth inhibition or in response to metabolic imbalances and DNA damage 50. The 
inactivation of any of these TSGs can lead to uncontrolled cell proliferation, an important 
hallmark of cancer 51. A second class of TSGs are responsible for proofreading DNA and  
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repairing damaged DNA during cell division, as errors in DNA replication can contribute to 
carcinogenesis 50,52. When TSGs involved in DNA proofreading and repair are inactivated, cells 
with cancer-promoting mutations will progressively divide and accumulate additional 
detrimental mutations, leading to genomic instability and cancer 51,52. Generally, in a normal cell, 
if there is too much DNA damage that is beyond the repairing capabilities of the DNA repair 
genes, the cell undergoes apoptosis 52. Some TSGs are involved in triggering apoptosis 50. If 
these apoptosis-initiating TSGs are impaired, apoptosis does not occur and damaged cells 
continue to proliferate, leading to cancer 51. 
Knudson’s two-hit hypothesis is currently used to describe the downregulation of TSGs in both 
hereditary and sporadic cancers. This hypothesis states that in order cancer to occur, both alleles 
of a TSG must be inactivated 51,53. In hereditary cancers, patients exhibit a germline mutation in 
one allele of a TSG that will predispose them to cancer (first hit), but tumour formation will only 
occur if the remaining functional allele is inactivated by a somatic mutation during the patients’ 
lifetime (second hit) 51,53. Conversely, sporadic cancers occur after two somatic mutations 
inactivate both functional alleles of a TSG in a single cell 54. Although most TSGs follow 
Knudson’s two-hit hypothesis, emerging evidence suggests that some TSGs do not require the 
inactivation of both functional alleles to result in tumour initiation or progression. Knudson 
states that if only one allele is inactivated, the remaining allele is able to maintain the function of 
the TSG in the cell 53. New evidence suggests that some TSGs might be haploinsufficient, 
meaning that inactivation of one allele of a TSG is enough to prevent proper regulation and 
function 54,55. There are three proposed mechanisms by which the phenomenon of 
haploinsufficiency occurs. In the first mechanism, reduced expression levels of gene product are  
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unable to effectively inhibit the activity of downstream targets involved in cell growth 51,54. The 
second mechanism of haploinsufficiency involves dominant-negative effects whereby the mutant 
allele produces a gene product that acts as an antagonist against the wild-type gene products 51,54. 
Lastly, the third mechanism of haploinsufficiency describes transcriptional silencing of wild-type 
alleles through alterations in the expression or regulation of transcriptional machinery 51. As 
downregulation of TSGs are crucial in tumour initiation and progression, it is important to 
understand the mechanisms by which TSG expression decreases. 
Downregulation of TSGs generally occurs as a result of mutation, gene deletion, epigenetic 
silencing, or a combination of these events 54,56. Missense mutations involve the substitution of a 
nucleic acid that alters the amino acid composition of a protein. This type of event can alter the 
structure of the protein, which, in turn, can prevent proper functioning of the protein, rendering it 
inactive 56. Secondly, nondisjunction events can occur through errors in cell division. The 
missegregation of chromosomes can result in entire chromosomal deletions or amplifications. 
Abnormal mitotic recombination during cell division can also result in deletions, insertions and 
translocations that inactivate TSGs. Interestingly, it has been reported that cancerous cells will 
lose an average of 25-30% of alleles that were present in normal cells, with some cancer cells 
losing up to 75% of alleles that were present in normal cells, demonstrating the high prevalence 
of LOH events in cancer 57. Epigenetic silencing of TSGs occurs through CpG methylation 58,59. 
This mechanism involves the addition of methyl groups to cytosine bases at various CpG sites in 
the promoter region 43. The hypermethylation of TSG promoters prevents transcriptional 
machinery from binding to the promoter region, thereby silencing transcription 60. In addition, 
recent studies have implicated microRNA activity in the downregulation of TSGs in human 
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cancers, but this mechanism is still being investigated 61. We can speculate that RBM5 
downregulation is the result of at least one, or a combination, of these events. 
1.4 Lung Cancer 
Lung cancer is the leading cause of cancer-related deaths in Canada, accounting for over 25% of 
all cancer deaths 62. In Canada,  27% of lung cancer patients are diagnosed at Stage 3, while  
48% of lung cancer diagnoses are made when patients’ cancers are at Stage 4 and exhibit distant 
metastasis 63. Although patients with early-stage lung cancer typically have a better response to 
treatment, 35-50% of those patients relapse within 5 years 64. Late stage diagnosis and disease 
relapse are responsible for a 5 year survival rate of 17% among lung cancer patients 63. Due to 
the high mortality rates associated with this disease, it is  prudent that we broaden our knowledge 
and understanding of the molecular events that occur in lung cancer. 
1.4.1 Lung Cancer and Smoking 
Tobacco-smoke exposure is the leading cause of lung cancer, as 85% of lung cancer patients are 
current or former smokers 65. Through the act of smoking, smokers are exposed to over 4000 
chemical constituents, with approximately 100 of those constituents being known mutagens and 
carcinogens 65,66. There are two ways in which smokers are exposed to these various compounds. 
The primary method of exposure is through mainstream smoke, when the smoker inhales air 
through the cigarette 65. Mainstream smoke consists of both vapour and particulate phases 65,66. 
The vapour phase contains over 500 chemical compounds, while the particulate phase consists of 
over 3500 chemical compounds 65,66. Sidestream smoke is the second route of exposure, 
involving the inhalation of smoke in the surrounding air between puffs 65. This type of smoke 
also accounts for second-hand smoke exposure in non-smokers, however, second-hand smoke 
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exposure is responsible for only 1.6% of lung cancers 67. The mutagens in tobacco smoke, 
whether in mainstream smoke or sidestream smoke, inflict DNA damage though the formation of 
DNA adducts, transversions (generally GT) within DNA sequences, and DNA methylation 
(especially hypermethylation of the promoter region of tumor suppressor genes) 65,66.  
Although lung cancer generally occurs in current and former smokers, only 10% of smokers 
develop lung cancer 68. The reason for this is unknown, but it has been postulated that lung 
cancer risk in smokers is related to factors such as the type of cigarette smoked, the presence of a 
filter, the depth of inhalation, the length of inhalation, as well as genetic factors 65,69. In fact, 
differences in smoking habits may even contribute to differences in clinical presentation, lung 
cancer histology, and even treatment outcomes 70. Lung cancer risk can be reduced upon 
smoking cessation 69. Despite this fact, former smokers continue to exhibit aberrant lesions and 
allelic losses in lung tissue, suggesting that many molecular changes that occur due to cigarette 
smoke exposure are not reversible 71. Conversely, some molecular changes, such as DNA 
methylation, are indeed reversible and can be reduced upon smoking cessation, however, 
aberrant methylation patterns are still demonstrated in former smokers 71,72. This further suggests 
that lung cancer caused by tobacco smoke exposure is going to be an outcome so long as 
cigarettes are available. 
1.4.2 Subtypes of Lung Cancer 
1.4.2.1 Small Cell Lung Cancer 
SCLC accounts for 10-15% of all lung cancers 65,73. It is considered the most aggressive type of 
lung cancer because the disease has generally metastasized at the time of diagnosis. Due to its 
aggressive nature, approximately 95% of patients with this diagnosis succumb to the disease 74,75. 
SCLC is characterized as a neuroendocrine tumour that originates in the epithelial cells of the 
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bronchi 65,76. SCLC harbours many genetic alterations, with mutation rates reported to be as high 
as 7.4 ± 1 protein-altering mutations per million base pairs 77. This trend is likely due to tobacco 
smoke exposure, as patients with SCLC are almost exclusively current or former smokers 75,76. 
Very little is known about molecular events causing SCLC. The major contributing factor to the 
absence of knowledge regarding genetic alterations in SCLC is due to the lack of available tissue 
specimens, as SCLC is generally not treated with surgery 77.  
Downregulation of TSGs is important for SCLC initiation, as TP53 and RB1 are mutated in over 
80% of cases, and considered possible driver genes 77. While these TSGs are downregulated by 
inactivating mutations, RBM5 generally does not harbour any inactivating mutations, indicating 
that downregulation of RBM5 does not occur through the same mechanism as other TSGs that 
are considered important to SCLC. Interestingly, one of the most common genetic alterations in 
SCLC involves the deletion of regions on the short arm of chromosome 3, in nearly 100% of 
cases 76. As RBM5 maps to this region, it is possible that gene deletion is the mechanism of 
decreased RBM5 expression in SCLC. This notion is substantiated by the fact that 3p21.3 
undergoes LOH in 95% of SCLCs 45-47. 
1.4.2.2 Non-small Cell Lung Cancer 
NSCLC is the most frequently diagnosed subtype of lung cancer, accounting for 85-90% of all 
lung cancers 67,76. NSCLC can be further categorized into ADC, SqCC and large cell carcinoma 
76. For the purpose of this study, we will be focusing solely on ADC and SqCC categories. 
1.4.2.2.1 Adenocarcinoma 
ADC is the most frequently diagnosed subtype of NSCLC in North America 78. This type of 
NSCLC originates in epithelial cells located on the periphery of the lungs, and is the least related 
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to smoking 69,79,80. In fact, never-smokers account for 15% of patients within this category, and 
many former smokers also develop ADC instead of other lung cancer subtypes 69. This type of 
NSCLC also predominantly presents itself in women instead of men 70. A study of 183 ADC 
tumour and non-tumor pairs revealed that the mean exonic mutation rate in ADC is 12.0 
events/megabase 78. Mutation rates in ADC are generally higher in smokers, most often in the 
form of CA transversions 81. Smokers most often present KRAS activating mutations in 33% of 
patients 81. Never-smokers and light smokers generally will not harbour KRAS mutations, but 
instead will express EGFR mutations that are mutually exclusive with KRAS mutations 81.  
Mutations in TSGs are also common in ADC. Mutations of TP53 are the most common, and 
have been reported to appear in 46% of ADC tumours 81. In addition, ADC tumours may also 
exhibit mutations in TSGs such as STK11 (17%), KEAP1 (17%), NF1 (11%), RB1 (4%) and 
CDK2NA (4%) 78,81. Some ADC tumours will also exhibit translocations in ALK, RET and ROS, 
but in a very small percentage of patients 78,81. Over 2000 gene deletions have been identified in 
ADC tumours 78. The most common deletion regions have been reported on chromosomes 3p, 
4q, 5q, 6q, 8p, 9 and 13q 76. Given the fact that deletions on chromosome 3p are common in 
ADC, LOH at 3p21.3 is a likely mechanism of RBM5 downregulation in this subtype of 
NSCLC. 
1.4.2.2.2 Squamous Cell Carcinoma 
SqCC is the subtype of NSCLC that is most related to smoking, as over 90% of patients 
diagnosed with this disease are either current or former smokers 76. Patients with SqCC are 
generally also heavier smokers, in comparison to current and former smokers that develop ADC 
69,70. Unlike ADC, SqCC predominately occurs in males 70. This subtype of lung cancer generally 
arises in the squamous epithelial cells of the bronchi 69,76,80. A study completed by The Cancer 
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Genome Atlas (TCGA) identified an average of 360 exonic mutations, 323 altered copy number 
segments and 165 genomic rearrangements per tumour 82. Interestingly, the number of copy 
number alterations detected in SqCC was higher than other molecular profiling endeavours by 
the TCGA 82. This finding has also been noted in other studies that have found a greater number 
of DNA deletions in SqCC compared to ADC 79. Deletions in SqCC are common, most often 
occurring on chromosome 3p, but also occurring on chromosomes 4q, 5q, 8p, 9p, 10q, 11p, 13q, 
17p, 18q and 21q 76. Since deletions on the short arm of chromosome 3p are common in both 
SqCC and ADC, it is possible that the RBM5 gene is deleted in both subtypes of NSCLC. 
1.4.2.3 Classification of Lung Cancer Subtypes 
1.4.2.3.1 SCLC Staging 
SCLC is not staged according to the TNM classification like most other cancers. Instead, SCLC 
is classified using a two-stage system devised by the Veteran’s Administration Lung Study 
Group 73. This two-stage system encompasses both limited stage (LS) and extensive stage (ES) 
classifications 73,75,76,83. LS includes SCLC tumours that are localized to the chest and within a 
single field of radiation 73,75,83. In order to fit within this criteria, the tumor must be isolated to a 
single lung, the mediastinum, and/or the lymph nodes located nearby and on the same side of the 
body as the lung tumour 73,75,83. Approximately 40% of SCLC patients fit within this category 
74,75. Alternately, the remaining 60% of SCLC patients diagnosed with ES have tumours that 
extend beyond a single field of radiation as the cancer has generally metastasized to either the 
other lung, brain, liver, bone, or lymph nodes located away from the original tumour 74,75,83. For 
both stages, the survival outcomes are generally not favourable as over 95% of patients will 
eventually succumb to the disease 74,75. Despite the fact that 80% of LS patients will show a 
complete response to treatment, the 5-year survival rate is 10-17%, with the median survival time 
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being approximately 17 months 74,75,84. Due to the extent of metastasis in ES patients, only 20% 
of patients will show a response to treatment. Since the majority of ES patients will not respond 
to treatment, the 5-year survival rate is only 2%, with the median survival time being 
approximately 7 months 74,75,85. Since most patients receive an ES diagnosis, it is necessary that 
we identify methods to screen at-risk populations, whether through improved imaging 
technologies or through novel biomarkers that can help to detect SCLC in early stages, so that 
patients can receive more effective treatments and increase survival outcomes. 
1.4.2.3.2 NSCLC Staging and Pathology 
NSCLC is classified according to the TNM Classification System (Table 1) 76. The primary 
tumour (T) is staged based on metrics such as the size of the primary tumour and the location of 
the primary tumor, followed by examination of metastasis to regional lymph nodes (N) and 
distant metastasis (M) to other organs or other regions of the lung 76. Based on the results of the 
TNM staging, patients are organized into prognostic groupings, ranging from Stages I-IV, with 
patients in earlier stages having a more favourable prognosis 64. In addition to use of the TNM 
Classification System, NSCLC tumours are also graded using a four-tier grading system, 
allowing clinicians to better predict how the cancer will grow and spread 76,86. The grade of the 
primary tumour is evaluated based on how differentiated tumour cells appear in comparison to 
normal lung cells. Grade 1, also known as “well-differentiated” cells are considered low grade as 
the cancer cells appear to be very similar to normal lung tissue 76,86. These types of tumours are 
likely to be slower growing and less aggressive 76,86. Grade 2 tumours are considered 
intermediate grade or “moderately differentiated” 76,86. The most aggressive tumours are those 
that are grades 3 and 4, also known as “poorly differentiated” and “undifferentiated,” 
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respectively 76,86. These high-grade tumours do not appear similar to normal lung tissue, and are 
likely to grow quickly and spread, contributing to a poor prognosis 76,86. 
Table 1 TNM Classification of Lung Tumours 
Primary Tumor (T) 
X Cannot be assessed 
0 No evidence of primary tumour 
1 Tumour is ≤3 cm in the greatest dimension, surrounded by the lung or visceral pleura, without 
bronchoscopic evidence of invasion more proximal than the main bronchus 
1a Tumour is ≤2 cm in the greatest dimension 
1b Tumour is >2 cm but ≤3 cm in the greatest dimension 
2 Tumour is >3 cm in greatest dimension with involvement of the main bronchus, ≥2 cm distal to the carina, 
invades visceral pleura, or associated with atelectasis or obstructive pneumonitis that extends to the hilar 
region without involving the entire lung 
2a Tumour is >3 cm but ≤5 cm in the greatest dimension 
2b Tumour is >5 cm but ≤7 cm in the greatest dimension 
3 Tumour is >7 cm and invades the chest wall, diaphragm, mediastinal pleura, or parietal pericardium 
OR 
Tumour <2 cm in the main bronchus distal to the carina without involvement of the carina 
OR 
Tumour is associated with atelectasis or obstructive pneumonitis of the entire lung 
4 Tumour of any size that invades the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, 
or carina 
OR 
Separate tumour nodules in a different ipsilateral lobe 
Regional Lymph Nodes (N) 
X Cannot be assessed 
0 No lymph node metastasis 
1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes 
2 Metastasis in ipsilateral mediastinal and/or subcarnial lymph nodes 
3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or 
subclavicular lymph nodes 
Distant Metastasis (M) 
X Cannot be assessed 
0 No distant metastasis 
1 Distant metastasis, including separate tumor nodules in a different ipsilateral or contralateral lobe 
Note: Table was adapted from WHO Classification of Tumours of the Lung76 
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1.5 Study Hypothesis and Objectives 
In the context of what has been reported in the literature, we know that RBM5 is downregulated 
in most lung cancers, more so in the lung cancers of smokers compared to never-smokers 40. This 
finding suggests that there are two mechanisms that regulate RBM5 expression, one of which is 
smoking related. To date, these mechanisms have not been elucidated.  Given the fact that the 
genes located in the common 3p21.3 deletion region are rarely mutated, and protein-altering 
mutations have not been detected in RBM5, mutation is unlikely to be a mechanism of RBM5 
downregulation 13,39,42. Since tobacco smoke exposure has been shown to influence promoter 
hypermethylation, and RBM5 is more frequently downregulated in lung tumours from smokers 
compared to lung tumours from never-smokers, it is conceivable that promoter hypermethylation 
may be one of the mechanisms by which RBM5 is downregulated 65,66,71,72. In support of this, 
many of the TSGs in the common 3p21.3 deletion region have been shown to undergo promoter 
hypermethylation, leading to reduced and/or loss of expression 39,46,87. Although the sole RBM5 
promoter hypermethylation study found no evidence of promoter hypermethylation, there were a 
number of CpG sites that were not examined, and tobacco smoke exposure was not taken into 
account 10,44. Therefore, at this point in time, promoter hypermethylation cannot be ruled out as a 
mechanism of RBM5 downregulation. For many TSGs within the common 3p21.3 deletion 
region, both promoter hypermethylation and allele loss have been observed 39,46,87. As previously 
mentioned, the RBM5 gene resides in the region of 3p21.3 that undergoes LOH in most lung 
cancers and even in the normal bronchial epithelium of smokers 39,47. These observations suggest 
that gene deletion may be another mechanism by which RBM5 is downregulated, potentially in 
relation to tobacco smoke. 
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The working hypothesis for this thesis was that deletion of the RBM5 gene was one of the 
mechanisms by which RBM5 was downregulated in the lung cancers of smokers. The objective 
of this study was to determine if significantly decreased levels of RBM5 expression in the 
NSCLCs of smokers was related to RBM5 deletion. To accomplish this, we obtained non-tumour 
and tumour tissues, and tobacco smoke exposure data from patients diagnosed with NSCLC, 
collected at Health Sciences North (HSN) over the course of one year. DNA and RNA were 
extracted from these tissue specimens. Firstly, the study cohort was confirmed as representative, 
having downregulated RBM5 expression in tumour, compared to non-tumour tissue. Secondly, 
RBM5 gene copy number studies were carried out. Statistical analyses were carried out to 
determine if RBM5 gene copy number was (1) significantly decreased in tumours, and (2) 
associated with tobacco smoke exposure. Statistical power for the analyses relating to RBM5 
gene copy number and tobacco smoke exposure was limited due to the fact that we received 
tissue samples from only six never-smokers diagnosed with NSCLC. Since RBM5 deletions were 
not frequently detected in the HSN NSCLC cohort, the study objectives were broadened to 
examine RBM5 gene copy number in SCLC DNA samples, obtained through collaboration.  
For further confirmation that RBM5 was downregulated in NSCLC, changes in RBM5 protein 
expression between non-tumour and tumour pairs from patients diagnosed with NSCLC were 
examined. The change in RBM5 protein expression in these samples was more complex than had 
been anticipated, and, because protein expression levels were not required to enable resolution of 
the objectives, protein data were provided as an appendix. 
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Chapter 2  
2 Materials and Methods 
2.1 Test Samples 
2.1.1 Test Sample Procurement 
The studies completed in this thesis were carried out using samples from two sources. Tissue 
samples were obtained from HSN, while DNA was obtained from a collaborator. 
2.1.1.1 Health Sciences North Lung Tissue 
Lung tissue was procured from 103 patients treated at HSN in Sudbury, Ontario, Canada 
between May 2014 and May 2015. All tissue was acquired with informed consent, according to 
the Institutional Research Ethics Board guidelines. All tissue was obtained from thoracotomies, 
and most was representative of invasive carcinoma. Non-tumour tissue was obtained from the 
periphery of each tumour at the time of surgery, and designated as non-tumour at that time. 
Procured tissue was immediately snap frozen in liquid nitrogen for 5 minutes, and then stored at 
-80°C. The procured tissue was accompanied with the corresponding pathology report, and a 
comprehensive smoking and mining questionnaire.  
A total of 188 tissue samples were received from 103 patients in the HSN cohort. A flow-chart 
describing the HSN cohort is included in Figure 3. These patients received various diagnoses that 
included ADC, SqCC, mixed NSCLC, metastatic carcinoma, among other medical conditions. 
For the purpose of this study, we focused solely on the patients diagnosed with ADC and SqCC. 
A total of 56 patients were diagnosed with ADC, and a total of 24 patients were diagnosed with 
SqCC. Six of the patients in the ADC group were never-smokers, while the remaining 50 ADC 
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Figure 3 Flow-chart of test samples procured from HSN. Test samples were received from 
103 patients diagnosed with ADC, SqCC, mixed NSCLC, metastatic carcinoma, among other 
medical conditions. A total of 56 patients were diagnosed with ADC, including six never-
smokers and 50 smokers. There were also 24 patients that were diagnosed with SqCC, all of 
whom were smokers. Tissue samples from patients diagnosed with mixed NSCLC, metastatic 
carcinoma, and other medical conditions, were not included in DNA or RNA analyses. In total, 
80 non-tumour and 65 tumour specimens were received. There were 65 patients with paired non-
tumour and tumour specimens. NS = never-smoker, S = smoker, NT = non-tumour, and T = 
tumour. 
103 patients
SqCCADC Mixed 
NSCLC
Metastatic 
carcinoma
OtherDiagnosis
# of patients
56 24 7 5 11# of patients
SNS SNS SNS SNS SNSSmoking status
6 50 24 1 6 1 4 4 70# of patients
NT T
Samples were not used in DNA or RNA analyses
NT T NT TTissue type
Total: 5
DNA: 5
RNA: 5
Total: 50
DNA: 50
RNA: 42
Total: 40
DNA: 40
RNA: 39
Total: 24
DNA: 24
RNA: 20
Total: 20
DNA: 20
RNA: 18
Total: 6
DNA: 6
RNA: 6
Paired DNA: 5
Paired RNA: 4
Paired DNA: 40
Paired RNA: 35
Paired DNA: 20
Paired RNA: 14
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patients, and the 24 SqCC patients, were either current or former smokers. Never-smokers were 
defined as patients who had smoked less than 100 cigarettes in their lifetime, while the smokers 
were defined as patients who were current or former smokers, exposed to ≥100 cigarettes 71. Due 
to the fact that we had only received tissue samples from six never-smokers diagnosed with 
ADC, our statistical capabilities were limited when analyzing the role of tobacco smoke 
exposure on RBM5 copy number and expression in tumours. For the patients that were 
considered smokers, tobacco smoke exposure was measured in pack-years, which was defined as 
the number of packs smoked per day multiplied by the number of years the patient smoked 70,80. 
A total of 80 non-tumour tissues and 65 non-tumour tissues were received. Paired non-tumour 
and tumour samples were received from 65 patients. DNA was obtained from all of the tissues, 
while RNA was obtained for most of the tissues. 
2.1.1.2 Slovakian SCLC DNA 
DNA from 44 SCLC patients was obtained from Dr. Erika Halasova of the Comenius University, 
in Bratislava, Slovakia. A flow-chart describing the Slovakian cohort is included in Figure 4. 
Only tumour DNA was obtained for this cohort. In regards to tobacco smoke exposure, eight 
patients were never-smokers, 34 patients were smokers and two patients had an unknown 
smoking history. 
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Figure 4 Flow-chart of test samples procured from Slovakia. A total of 44 SCLC DNA 
samples were received from Slovakia. This cohort provided SCLC DNA from eight never-
smokers, 34 smokers, and two patients of unknown smoking history. NS = never-smoker, S = 
smoker, T = tumour. 
2.1.2 Tissue Preparation 
DNA, RNA and protein were isolated from the HSN lung specimens, using the Allprep 
DNA/RNA/Protein Mini Kit (Qiagen, Mississauga, Ontario, Canada), according to the 
manufacturer’s instructions, and as described immediately below. 
2.1.2.1 Pulverization and Homogenization 
Approximately 20 milligrams (mg) of lung tissue was cut using a sterile blade and transferred to 
a tissue pulverizer (Bessman, Fisher Scientific, Ottawa, Ontario, Canada) that had been 
44 patients
SCLCDiagnosis
# of patients
44# of patients
SNSSmoking status
8 34# of patients
T T TTissue type
Total DNA: 8 Total DNA: 34 Total DNA: 2
Unknown
2
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immersed in liquid nitrogen for 10 minutes. The mortar was then placed in the tissue pulverizer 
and smashed with a hammer until the tissue was broken up into fine powder-like consistency. 
Tissue was transferred to a microfuge tube containing 600 microliters (μl) of Buffer RLT 
(Qiagen) and 0.14 millimolar (mM) β-mercaptoethanol (Sigma, Oakville, Ontario, Canada), and 
subsequently homogenized using a Polytron PT 1300 D Homogenizer (Kinematica, Lucerne, 
Switzerland). The resulting lysate was centrifuged for 3 minutes at 17 000 x g at 21°C, to pellet 
any tissue that did not homogenize in solution. The supernatant was subsequently transferred to 
an Allprep DNA spin column (Qiagen). 
2.1.2.2 Genomic DNA Purification 
DNA was extracted, according to the manufacturer’s instructions. The Allprep DNA spin column 
containing the supernatant was centrifuged at 8 000 x g for 30 seconds at 21°C. The resulting 
flow-through was placed at 21°C for subsequent RNA purification, while the DNA on the spin 
column was washed with Buffers AW1 and AW2 (Qiagen). Wash buffers were eluted from the 
spin column by centrifugation at 8 000 x g for 30 seconds and 17 000 x g for 2 minutes at 21°C, 
for Buffers AW1 and AW2, respectively. To elute the DNA, Buffer EB (Qiagen), pre-heated to 
70°C, was applied to the Allprep DNA spin column and incubated at room 21°C for 2 minutes. 
Following incubation, DNA was eluted by centrifugation at 8 000 x g for 1 minute at 21°C, and 
subsequently stored at -80°C. DNA was quantified, using the Nanodrop 2000c 
Spectrophotometer (Thermo Scientific, Waltham, Massachusetts, U.S.A.). 
2.1.2.3 Total RNA Purification 
RNA was extracted according to the manufacturer’s instructions. The initial flow-through, which 
had been stored at 21°C during DNA purification, was combined with 100% ethanol, to 
precipitate the RNA, and transferred to the RNeasy spin column (Qiagen). The spin column was 
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then centrifuged at 8 000 x g for 15 seconds at 21°C. The flow-through, containing the protein, 
was saved for subsequent protein precipitation, while the RNA that remained within the column 
was subjected to subsequent wash steps. The RNA was washed with Buffer RW1 (Qiagen), by 
centrifugation at 8 000 x g for 15 seconds at 21°C. Flow-through was discarded and the RNeasy 
column was then washed twice with Buffer RPE and centrifuged at 8 000 x g, for 30 seconds and 
2 minutes at 21°C, respectively. RNase-free water was then added to the column and RNA was 
eluted by centrifugation at 8 000 x g for 1 minute at 21°C. The eluted RNA was quantified, using 
the Nanodrop 2000c Spectrophotometer (Thermo Scientific), then stored at -80°C. 
2.1.2.4 Total Protein Precipitation 
Protein was extracted according to the manufacturer’s instructions. The protein from the flow-
through, which had been stored at 21°C during RNA purification, was precipitated by incubation 
in Buffer APP (Qiagen) and at 21°C for 10 minutes.  The mixture was then centrifuged at 17 000 
x g for 10 minutes at 21°C, to form a protein pellet. The supernatant was discarded and the 
resulting protein pellet was washed with 70% ethanol then centrifuged at 17 000 x g for 1 minute 
at 21°C. Any excess ethanol was removed using a pipette tip, and the pellet was left to dry at 
21°C for 15 minutes. Since it was previously determined that the resulting protein pellets were 
difficult to resuspend, the protein pellet was then resuspended in 0.2% RapiGest (Waters, 
Mississauga, Ontario) in 50 mM ammonium bicarbonate to increase protein solubility. This 
solution was heated at 100°C for 5 minutes, and then left on ice for an additional 5 minutes. The 
solution was centrifuged at 17 000 x g for 1 minute at 21°C, to form a protein pellet. The 
remaining RapiGest was discarded and the protein pellet was resuspended in Buffer ALO 
(Qiagen). This solution was heated at 95°C for 5 minutes, and then centrifuged at 17 000 x g at 
21°C for 1 minute. Protein was quantified using the Bio-Rad DC Protein Assay Kit (Bio-Rad 
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Laboratories, Hercules, U.S.A.), using bovine serum albumin (Life Technologies) as a standard. 
Once protein was quantified, it was stored at -80°C. 
2.2 Control Samples 
The BEAS-2B human bronchial epithelial cell line was obtained from ATCC (catalogue number: 
CRL-9609). These cells were used as a control sample for all DNA copy number calculations 
and mRNA expression calculations, following confirmation of a 2n RBM5 gene copy number 
(see Chapter 3). As such, RBM5 copy number in the test samples was compared to the BEAS-2B 
cells. For consistency, RBM5 mRNA expression in the test samples was also compared to the 
BEAS-2B cells. 
2.2.1 Cell Culture 
2.2.1.1 Preparation for Cell Culture 
Prior to growing cells, 10 cm2 plates were coated with 0.01 mg/ml BSA (Life Technologies, 
Burlington, Ontario, Canada), 0.03 mg/ml Collagen from rat tail (Sigma), 0.01 mg/ml 
Fibronectin (Sigma) and LHC-9 medium (Life Technologies), and placed in an incubator at 37°C 
overnight. In the morning, the coated plates were placed in a tupperware container, and placed in 
a drawer at room temperature until they were needed, within 48 hours. Prior to thawing cells, 
plates were washed twice with 1X PBS (Life Technologies) and then sterilized for 30 minutes 
under ultraviolet light. 
2.2.1.2 Thawing 
BEAS-2B cells with a passage number of 41 were thawed and 1 mL of the freezing medium was 
removed by dilution in 9 mL LHC-9 media and centrifugation for 5 minutes at 200 x g at 21°C. 
The supernatant was removed and the cell pellet was resuspended in LHC-9 media, and then 
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transferred to sterilized coated plates. Cells were placed in an incubator at 37°C and grown over 
a period of 2-3 days until cells were approximately 70-80% confluent. 
2.2.1.3 Passaging 
To pass cells, medium was removed from the plates and the cells were washed twice with 1X 
PBS. Trypsin/EDTA/PVP solution (0.25% Trypsin [Life Technologies], 0.53 mM EDTA [Bio-
Rad] and 0.5% PVP [Sigma]) was then added to the plate and placed in the incubator at 37°C for 
5-10 minutes, until the cells appeared to have lifted from the coating. Trypsin inhibitor was then 
added to the plate, followed by a volume of LHC-9 medium. The cells were removed from the 
plate, using a pipette, and transferred to a conical tube that was centrifuged at 200 x g for 5 
minutes at 21°C. The supernatant was discarded and the pellet was resuspended in LHC-9 
medium then dispensed at a 1:10 dilution of LHC-9 medium into sterilized coated plates. Cells 
were then placed in the incubator at 37°C and left to grow over a 2-3 day period. BEAS-2B cells 
with passage numbers of 43 and 44 were harvested, and the DNA, RNA and protein were 
extracted using the DNA/RNA/Protein Mini Kit (Qiagen), to use as a control for gene copy 
number and expression analyses. 
2.2.2 RBM5 Gene Copy Number in BEAS-2B Cells 
For RBM5 copy number analyses, it was important to identify a control sample that retained a 2n 
RBM5 copy number from which RBM5 copy number in the test samples could be compared to. 
The BEAS-2B cell line is a “normal” non-tumorigenic lung epithelial cell line 36. As such, the 
cell line was expected to retain a normal 2n copy number of RBM5. To confirm that the BEAS-
2B cell line retained a normal (2n) RBM5 copy number, the RBM5 copy number in the BEAS-2B 
cell line was compared to the RBM5 copy number in non-tumour and SCLC tumour tissues from 
two patients that were obtained from the Ontario Tumour Bank (OTB), and two cell lines. DNA 
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and RNA were extracted from the OTB samples, and RNA-seq was performed on the RNA 16. 
The RNA-seq analysis found that RBM5 mRNA expression in the SCLC tumours decreased by 
approximately 50%, compared to the non-tumour lung tissue, in both patients 16. Loss of 50% of 
RBM5 mRNA expression in both patients suggested loss of one RBM5 allele in the tumour 
samples, making the OTB samples an appropriate RBM5 copy number comparator. Additionally, 
RBM5 copy number in the BEAS-2B cell line was compared to the GLC20 SCLC cell line 88 and 
the BT-474 (ATCC, catalog number: HTB-20) human breast ductal carcinoma cell line. The 
GLC20 cell line was chosen as a comparator because it has a homozygous deletion of RBM5 
16,39. The BT-474 cell line was also chosen as a comparator because it does not contain any 
alterations on the short arm of chromosome 3 (ATCC, catalog number: HTB-20), the region to 
which RBM5 maps to, and, therefore, is likely to retain a normal (2n) RBM5 copy number. 
DNA, RNA and protein were extracted from the cell lines and the tissue samples using the 
Allprep DNA/RNA/Protein Mini Kit (Qiagen), described in section 2.1.2. RBM5 copy number 
analyses were completed using the qPCR technique and primers described in section 2.5.1, and 
the calculation described in section 2.4.3. 
2.3 Reference Gene Selection 
A literature review was completed to identify potentially suitable reference genes for this study, 
meaning genes did not change expression (for RNA) or copy number (for DNA) in the tumour, 
compared to the non-tumour, or in the smokers, compared to the never-smokers.  
2.3.1 Reference Genes for RNA Expression Analyses 
As the first objective of this study was to confirm that RBM5 was downregulated in NSCLC 
tumours, to prove that our cohort was representative of the literature, reference genes that did not 
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change expression between non-tumour and tumour tissue were necessary for accurate 
quantification of RBM5 expression. Two reference genes that were consistently shown to be 
equally expressed in NSCLC tumours and normal lung tissue were Ribosomal Protein Lateral 
Stalk Subunit P0 (RPLP0) and β-actin (ACTB) 89-93. The use of two reference genes, with the 
intention of averaging the two for normalization purposes, was acceptable for accuracy in mRNA 
expression calculations 91,93. 
The RPLP0 gene maps to 12q24.23, and codes for a protein that is a component of the 60S 
subunit of the ribosome. The RPLP0 primers used in this study were taken from an article 
written by Gresner and colleagues, published in 2009 89. The purpose of this study was to 
identify stably expressed reference genes for the reliable interpretation of SYBR qPCR data 
when comparing NSCLC tumours to normal lung tissues. In this study, RNA was extracted using 
the RNeasy Plus Mini Kit (Qiagen) from 20-25 mg of non-tumour and NSCLC tumour, from 
nine patients diagnosed with ADC and 12 patients diagnosed with SqCC. The extraction protocol 
utilized in this study was very similar to our protocol, and the researchers were also using a 
SYBR-based qPCR method, which we had also intended to use, making this study a suitable 
platform for reference gene consideration. Through the examination of Ct values, it was 
demonstrated that there was a slight difference of approximately one cycle in median Ct values 
between non-tumour and tumour RNA, but the difference was not great enough to cause 
inequality in expression values 89. The suitability of RPLP0 as a reference gene was 
demonstrated using three separate analyses, through the examination of relative expression, and 
through use of softwares including NormFinder and GeNorm 89. The suitability of RPLP0 as a 
reference gene for comparing normal lung tissue to NSCLC tumour tissue was also demonstrated 
in other analyses, using a similar platform as the Gresner et al. study 90-92.  
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The ACTB gene, on the other hand, maps to 7p22.1, and codes for a protein that is a component 
of the cytoskeletal structure. One of the reasons ACTB was chosen as a reference gene for 
mRNA analyses was because ACTB was also used as a normalization control in the protein 
analyses, included in the Appendix section. It was important to maintain consistency in 
normalization at both mRNA and protein levels, which is why ACTB was chosen as a 
normalization control for both mRNA and protein analyses. ACTB was shown to be a suitable 
reference gene for qPCR analyses, albeit for Taqman-based qPCR analyses, in a study completed 
by Saviozzi and colleagues in 2006 91. The purpose of the Saviozzi et al. study was to evaluate a 
number of reference genes to determine which ones were the most suitable to use for accurate 
normalization of gene expression in paired non-tumour and NSCLC tumour tissue 91. Paired 
fresh-frozen non-tumour and NSCLC tumour samples were obtained from 18 patients diagnosed 
with NSCLC, including seven patients diagnosed with ADC, 11 patients diagnosed with SqCC, 
and one patient diagnosed with bronchioloalveolar carcinoma 91. RNA was isolated from 
samples using two methods: the RNeasy 96 Kit (Qiagen) and the Biorobot 8000 (Qiagen) 91. 
Looking at difference in median Ct values, it appeared as though ACTB demonstrated a 
difference of approximately one cycle between non-tumour and tumour tissue 91. Since the data 
were shown to follow a normal distribution, it can be assumed that the median Ct values are 
equal to the mean Ct values 91. This difference of one Ct value was not shown to influence 
expression as the fold-change in expression levels between non-tumour and tumour tissue was 
relatively low and demonstrated less variation, compared to other reference genes 91. From this 
study, we were convinced that ACTB was a suitable reference gene for mRNA expression 
analyses. As the ACTB primers specific to the Saviozzi study were part of a commercially 
available Taqman primer/probe kit, but we intended on using a SYBR-based qPCR assay, it was 
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necessary to look elsewhere for primers for our study. ACTB primers for this study were 
obtained from a publication by Radonic et al. in 2004, a study that also provided information on 
selecting suitable reference genes for qPCR 93. 
As this study also took tobacco smoke exposure history into consideration for subsequent 
analyses, it was also important to confirm that expression of the reference genes was not altered 
by tobacco smoke exposure. Although there were no studies that examined changes in reference 
genes after exposure to tobacco smoke, both RPLP0 and ACTB have been used in combination 
as reference genes in the literature for studies that examined MUC5AC RNA expression in the 
airway epithelium of smokers and never-smokers, as well as global miRNA expression in 
alveolar macrophages of smokers and never-smokers, indicating their suitability as reference 
genes for tobacco smoke-related expression analyses, especially when used in combination 94,95. 
2.3.2 Reference Genes for DNA Copy Number Analyses 
As the objective of this study was to determine if the significantly decreased RBM5 expression 
in the NSCLCs of smokers was the result of gene deletion, it was necessary to identify reference 
genes that maintained a normal (2n) copy number in non-tumour vs tumour tissue and in never-
smokers vs smokers. Upon review of the literature, it was clear that there were not any 
publications that examined suitable reference genes for quantification of gene copy number in 
lung. As such, publications that examined reference genes at the mRNA level in lung tissue were 
utilized. We inferred that if expression of reference genes were consistent and equal between 
non-tumour and NSCLC tumour mRNA, it was unlikely that the DNA was altered. Following 
identification of candidates that did not change expression, additional review of the literature was 
carried out to ensure that the chromosomal region to which each gene mapped was not 
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commonly altered in cancer. These genes were then tested for suitability in subsequent analyses 
(Chapter 3). 
Pumilio RNA Binding Family Member 1 (PUM1), which maps to 1p35.2, is a type of RBP that 
is involved in the translational regulation of various mRNA targets as a repressor of translation. 
Its RNA was shown to be stably expressed in non-tumour and NSCLC tumour tissue 92. In fact, a 
study completed by Soes et al. in 2013, found that PUM1 was one of the most stably expressed 
genes among 23 candidate reference genes. The short arm of chromosome 1 was not shown to be 
commonly altered in NSCLCs, including ADC and SqCC, and was not shown to be commonly 
altered in SCLC either, as chromosome 1 is not one of the common deletion or duplication 
regions of the lung cancer genome 76. Alterations in chromosome 1 have been observed in some 
lung cancers, including the amplification of 1q21-q25 in SqCC and LOH at 1p36 in both SCLC 
and NSCLC, but the 1p35 region was not altered in lung cancers, meaning that the PUM1 gene 
was likely neither deleted nor amplified, and the gene retained a normal (2n) copy number in 
lung cancers 76,96.  
In order to keep a level of consistency in reference genes across DNA copy number and mRNA 
expression analyses, RPLP0 was also considered as a candidate reference gene for DNA copy 
number analyses. As previously mentioned, RPLP0 was chosen as a reference gene for mRNA 
expression analyses because it was considered to be stably expressed in non-tumour and NSCLC 
tumour tissue in multiple studies 89-92. RPLP0 maps to the chromosomal region 12q24.23. The 
long arm of chromosome 12 was not included in the commonly deleted or amplified regions of 
the lung cancer genome 76. Only the short arm of chromosome 12 was shown to be amplified, in 
SqCC, specifically 97. Given this information, it did not appear as if the RPLP0 gene was likely 
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to undergo copy number gains or deletions, and was, therefore, likely suitable to use as a 
reference gene for copy number analyses, in combination with PUM1. 
Since RBM5 copy number was compared between smokers and never-smokers in this study, it 
was crucial to confirm that aberrations at chromosome 1p35.2 and 12q24.23 did not occur as a 
result of tobacco smoke exposure. Since molecular aberrations in these chromosomal regions did 
not occur in lung cancers that were associated with tobacco smoke exposure, such as SqCC or 
SCLC, we inferred that these regions likely remained unaltered in patients with tobacco smoke 
exposure. 
2.4 RBM5 mRNA Expression Analysis 
RNA expression was analysed in HSN test samples relative to the BEAS-2B control sample. 
RNA was reverse-transcribed into cDNA, and the cDNA was amplified using a SYBR-based 
qPCR method. RBM5 primers spanning exons 6 and 7 were used to measure RBM5 expression, 
while RPLP0 and ACTB primers spanning exons 2 and 3 and exons 1 and 2, respectively, were 
used as normalization controls. 
2.4.1 Reverse Transcription 
RNase-free water, containing 0.5 micrograms (μg) of RNA, was combined with 10 mM 
Deoxynucleotide Solution Mix (New England Biolabs, Pickering, Ontario, Canada) and 100 
μg/μl oligo-dT primer (Alpha DNA, Montreal, Quebec, Canada). This solution was incubated at 
65°C for 5 minutes, and then placed on ice. While on ice, 5X First Strand Buffer (Invitrogen) 
and 0.1 molar (M) dichlorodiphenyltrichloroethane (DTT) (Invitrogen) was added to the 
solution, then incubated at 42°C for 2 minutes. Finally, 200 U of MMLV Reverse Transcriptase 
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(Invitrogen) was added to the solution and incubated at 42°C for 50 minutes, followed by 70°C 
for 15 minutes. Resulting cDNA was stored at -20°C. 
2.4.2 Quantitative PCR (qPCR) 
For mRNA expression analyses, a SYBR-based qPCR assay was used. In this method, SYBR 
dye intercalates with double-stranded DNA, and its fluorescence increases with each successive 
cycle, as PCR product is amplified. When amplification of a gene reached an exponential phase, 
the cycle at which the exponential phase began, and rose above the background fluorescence, 
was referred to as the threshold cycle (Ct) 98-101. The Ct values were used for all expression 
calculations. Standard curves for each of the amplified genes were also constructed, and the 
slope of each standard was used to measure efficiency of the standard curve. The efficiency of 
the standard curve is important for understanding how efficiently the PCR amplicon doubled 
during the exponential phase 100. Ideally, the efficiency of the standard curve should have been 
close to 100%, but this was not always the case 100. Using both the Ct values and the efficiency 
of the standard curve, mRNA expression was calculated using a comparative Ct method. 
Furthermore, it was also important that the standard curve was linear across all data points, as 
denoted by an R2 value that was greater than 0.9 100. Any plates in which a standard curve had an 
R2 value below 0.9 were not used for mRNA expression calculations. 
For each patient sample, three technical replicates for each gene were examined on a single 96-
well plate, to control for technical errors. Duplicate assays were completed, to control for plate-
to-plate variability. Mean RBM5 mRNA expression values were calculated using the average of 
all six technical replicates. Outliers within each set of six technical replicates were identified 
using the Grubb’s test, which is capable of identifying only one outlier in each data set 102. When 
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a significant outlier was detected, the outlier value was removed from the calculation of the mean 
RBM5 mRNA expression value. 
cDNA samples were diluted in water and combined with iTaq Universal SYBR Green Supermix 
(Bio-Rad, Mississauga, Ontario, Canada), and 0.75 micromolar (μM) (RBM5, RPLP0 and 
ACTB) forward and reverse primers (Alpha DNA) (Table 2). Standard curves were prepared 
using a serial dilution of BEAS-2B cDNA, with dilutions ranging between 1:1 and 1:625. The 
qPCR reaction was performed on the Aria Mx Realtime PCR System (Agilent, Mississauga, 
Ontario, Canada) using the following program: 95°C for 5 minutes, followed by 40 cycles of 
95°C for 30 seconds, 60°C for 30 seconds and 72°C for 45 seconds, and concluded with one 
dissociation curve cycle consisting of temperatures ranging between 95°C and 60°C. The 
dissociation curve was used to confirm the specificity of PCR products and identify the presence 
of primer dimers and contaminants 100. 
Table 2 Primers used for mRNA qPCR analysis 
Gene Primer Primer Sequence (5’ > 3’) Exon 
Size of 
Amplicon 
(bp) 
Annealing 
Temperature  
(°C) 
   
   
RBM5 RBM5 Exon6F F: GTG TAA GCC GTG GTT TCG CCT TC 6 
108 60 
 
RBM5E7R R: TTG CAA TGT GCT TTC CTT GA 7 
   
   
RPLP0 RPLP0E2F F: CTG ATG GGC AAG AAC ACC AT 2 
115 60 
 RPLP0E3R R: GTG AGG TCC TCC TTG GTG AA  3 
            
ACTB ACTB-F F: CAG AGC CTC GCC TTT GCC GA  1 
111 60 
 ACTB-R R: GAA GCC GGC CTT GCA CAT GC  2 
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RBM5 primers were previously used in the Sutherland Lab for the measurement of RBM5 
expression by qPCR 103. RPLP0 primers were adapted from an article by Gresner and colleagues, 
and ACTB primers were adapted from an article by Radonic and colleagues, published in 2009 
and 2004, respectively 89,93. The specificity of the primers was confirmed using the online 
OligoAnalyzer 3.1 Tool (Integrated DNA Technologies, Coralville, Iowa, U.S.A.) and the 
efficiency of the primers was confirmed (Chapter 3). Reference genes were also validated for 
stable expression in non-tumour and tumour tissue (Chapter 3). 
2.4.3 Calculation of RBM5 mRNA Expression 
For calculation of RBM5 mRNA expression, based on a fold-change between a test sample and a 
control sample, the Pfaffl method was used, with the Hellemans correction 104,105. The Pfaffl 
method measures the expression ratio of a test gene in a test sample and a control sample, and 
compares this ratio to the expression ratio of a single reference gene in a test sample and a 
control sample, and corrects for changes in standard curve efficiencies 99,101,104,105. Since the 
Pfaffl method only considers one reference gene, and more than one reference gene is now 
considered preferable for accurate quantification in qPCR analyses, the Hellemans correction 
was used 105.  
BEAS-2B RNA represented the standardized expression of RBM5 and reference genes, serving 
as the control against which all the HSN test samples, both non-tumour and tumour, were 
measured. Ct values were compared between control and test sample RNA, to calculate the fold-
changes in expression. These Ct comparisons were made for both the gene of interest, RBM5, 
and the reference genes, RPLP0 and ACTB. 
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Prior to using the Pfaffl method, the efficiency of the standard curve for each gene primer pair 
needs to be calculated (Equation 1). 
Equation 1: Efficiency = 10 (-1/slope) 
Using Equation 1, the calculated efficiency value that is reflective of 100% efficiency is an 
efficiency value of 2, as reflected by a slope of approximately -3.32 100. Reduced efficiency will 
result in an efficiency value below 2, while increased efficiency will result in an efficiency value 
above 2, according to Equation 1. 
Standard curve efficiencies between the primer pairs amplifying a test gene and the primer pairs 
amplifying each reference gene will likely not be identical, as may the standard curve 
efficiencies between the same primer pair used in plate replicates. When efficiency is below the 
ideal of 100%, and amplicon doubling capacity is decreased, the resultant Ct values would be 
higher than expected if the primers were 100% efficient. Alternatively, when efficiency is higher 
than 100%, the amplicon doubling capacity is increased, and the resultant Ct values would be 
lower than expected if the primers were 100%.  Therefore, interpretation of Ct values is 
meaningless unless primer efficiencies are known. 
Once efficiency values are calculated, Equation 2 is used to measure test gene expression in the 
test sample(s) compared to the control sample, while also normalizing test gene expression to the 
reference gene(s).  
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2.5 RBM5 DNA Copy Number Analysis 
A SYBR-based qPCR method was used for RBM5 copy number analyses. RBM5 gene copy 
number in the HSN and Slovakian test samples was measured relative to the BEAS-2B control 
sample, using a comparative Ct method. This method was nearly identical to the mRNA 
expression analyses described above. 
2.5.1 Quantitative PCR (qPCR) 
Similar to the mRNA analyses, a SYBR-based qPCR method was used. The Ct values of test 
samples and the control sample, as well as the efficiency of the standard curves, were necessary 
for calculation of RBM5 copy number. Standard curves were required to be linear for accurate 
quantification of RBM5 copy number, and, therefore, required an R2 value that was greater than 
0.9 100. 
For each patient sample, three technical replicates for each gene were examined on a single 96-
well plate to control for technical errors. Duplicate assays were completed, to control for plate-
to-plate variability. The 96-well plate set-up is displayed in Figure 5. Mean copy number values 
were calculated using the average of all six technical replicates. An outlier within each of the six 
technical replicates was identified using the Grubb’s test, which is capable of identifying only 
one outlier in each data set 102. If a significant outlier were detected, the outlier value was 
removed from the calculation of the mean copy number value.  
Equation 2: Test expression = 
Efficiency (test)
Ct control-Ct test
 Efficiency (Ref 1)Ct control-Ct test x Efficiency (Ref 2)Ct control-Ct test
2
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Samples were prepared using 25 ng of patient DNA, 1X All-in-One qPCR Mix (Genecopoeia, 
Rockville, Maryland, U.S.A.), and 1.5 μM (RBM5) or 0.75 μM (PUM1 and RPLP0) forward and 
reverse primers (Alpha DNA) (Table 3). BEAS-2B DNA was used as a control sample, and 
prepared identically to the test samples, with 25 ng of DNA. The 25 ng addition of test and 
control DNA was optimal, as the amplified DNA was expected to fall within the middle of the 
standard curve, for accurate interpolation of data. Standard curves containing DNA quantities 
Figure 5 96-well plate set-up for the RBM5 gene copy number qPCR assay. Three standard 
curves were constructed in triplicate, for RBM5, PUM1 and RPLP0, respectively, using BEAS-
2B DNA. Standard curves contained five data points, with BEAS-2B DNA quantities ranging 
from 100 ng-6.25 ng. Four test samples (Unknowns #1-4) and the BEAS-2B control sample were 
also included on the 96-well plate. RBM5, PUM1 and RPLP0 measurements were completed, in 
each test sample and the control sample, in triplicate, using 25 ng of DNA. No template controls 
(NTC) were included for each gene, in duplicate, using water in the place of DNA in the reaction 
mixture. 
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between 100 ng and 6.25 ng were prepared using a serial dilution of BEAS-2B DNA. The qPCR 
reaction was carried out using the AriaMx Realtime PCR System (Agilent), using the following 
program: 95°C for 5 minutes, followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds 
and 72°C for 45 seconds. Following amplification, one dissociation curve cycle consisting of 
temperatures ranging between 95°C and 60°C was completed for each sample and no template 
control (NTC), to confirm the specificity of the PCR products and identify any primer dimers or 
contaminants. 
RBM5 primers were designed by a former student in the Sutherland lab. Primers mapping to 
exon 1 of the RBM5 gene were chosen because it was in a region of the RBM5 gene that was 
transcribed, and also because it was the exon that was closest to the telomere of 3p. The 
placement of primers in exon 1 enabled detection of deletions that were likely due to loss of an 
entire allele, that was part of the 3p21.3 deletion region, and not loss of a partial segment of the 
RBM5 gene, that would have resulted in a truncated transcript. Forward and reverse primers were 
designed in exons 13 and 2 of PUM1 and RPLP0, respectively. The online OligoAnalyzer 3.1 
Tool (Integrated DNA Technologies) was used to confirm the specificity of the primers and the 
efficiency of the primers was confirmed in Chapter 3. Reference genes were also validated for 
stable expression in non-tumour and tumour tissue, and in smokers and never-smokers in 
Chapter 3. 
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Table 3 Primers used for DNA qPCR analyses 
Gene Primer Primer Sequence (5’ > 3’) Exon 
Size of 
Amplicon 
(bp) 
Annealing 
Temperature  
(°C) 
     
 
RBM5 QRBM5 E1F1 F: CGG AGG CGC CAT TTT GT 
1 72 60 
 
QRBM5 E1R1 R: GAA GCA GCA GTA GCG GTT CTG  
      PUM1 PUM1-F F: TGG ACC ATT TCG CCC TTT AG 
13 103 60 
 
PUM1-R R: CAG AGA GTT GTT GCC GTA GAA 
      RPLP0 RPLP0-F F: AGA TCC GCA TGT CCC TTC G  
2 66 60 
 
RPLP0-R R: CCT TGC GCA TCA TGG TGT T  
            
 
2.5.2 Calculation of RBM5 Copy Number 
Calculation of RBM5 copy number was also completed using the Pfaffl method with the 
Hellemans correction, exactly how RBM5 mRNA expression was calculated 99,104,105.  
The BEAS-2B cell line was used as the control sample for all copy number calculations. The cell 
line was experimentally determined to have two copies of the RBM5 gene (see Chapter 3). As the 
BEAS-2B cells had two copies of RBM5, it served as a platform that was representative of the 
results anticipated for normal (2n) copies of RBM5. Comparing the test samples to the control 
sample allowed us to calculate a relative copy number value for each of the test samples, that 
was reflective of fold-changes either equating to or deviating from a normal (2n) copy number. 
Equations 1and 2, as described in Section 2.4.3, were used to calculate the efficiency value and 
test gene copy number. 
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2.6 Statistical Analyses 
The strategy for statistical analyses completed in this study is described in Figure 6, through use 
of a flow-chart. Statistical analyses were carried out using GraphPad Prism 5 software 
(GraphPad Software Inc., San Diego, California, U.S.A.).  
Once RBM5 copy number or RBM5 expression values were calculated for each patient, data sets 
were examined to determine if they followed a normal distribution. To test for normality, the 
Shapiro-Wilk test was used 106. If the Shapiro-Wilk test resulted in a p-value of less than 0.05, 
the data were interpreted as not following a normal distribution. In such cases, non-parametric 
tests were used in subsequent analyses. If the resulting p-value was greater than or equal to 0.05, 
parametric tests were used in subsequent analyses. In this cohort, all data sets did not follow a 
normal distribution, and, therefore, non-parametric analyses were used. 
For continuous data, such as RBM5 mRNA expression, data was displayed in the form of a 
boxplot. The Tukey method was chosen to identify outliers, as it identifies outliers that do not fit 
within interquartile ranges, defined by the parameters of the boxplot 107. Non-parametric tests for 
continuous data sets included the Mann-Whitney test and the Wilcoxon signed-rank test. The 
Mann-Whitney test was used to compare the means of two independent variables (i.e. smoker vs 
never-smoker, or, patients with a 1n RBM5 copy number vs patients with a 2n RBM5 copy 
number) 108. If the Mann-Whitney test resulted in a two-tailed p-value of less than 0.05, then the 
difference between the means of the two groups was considered to be statistically significant. 
Another non-parametric test that was used throughout this study was the Wilcoxon signed-rank 
test, used to measure statistically significant differences in paired samples (i.e. non-tumour vs 
tumour, from the same patients) 109. If the difference in rank totals resulted in a p-value of less 
than 0.05, the difference was considered statistically significant.  
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For categorical data, such as RBM5 gene copy number, the data were displayed in the form of a 
bar graph. The 3x2 Fisher’s exact test was used to identify significant differences in categorical 
data from a contingency table 110. For this test, the proportion of patient samples that fit into a 
particular RBM5 copy number category (1n, 2n or 3n) was analysed. Differences in the 
proportion of samples that fit into a particular copy number category were compared between 
two groups (i.e. non-tumour vs tumour, smoker vs never-smoker). If the proportion of patient 
samples that fit into a particular copy number category was significantly different between the 
two groups, a two-tailed p-value of less than 0.05 was obtained using the 3x2 Fisher’s exact test. 
The Kruskal-Wallis test was used to examine the relationship between RBM5 copy number and 
RBM5 mRNA expression. This test determined if the medians between two or more groups were 
significantly different 111. Groups were established based on categorical data (i.e. copy number). 
Continuous data (i.e. expression) were then sorted according to the established groups. The 
Kruskal-Wallis test determined if there was a statistically significant difference between two or 
more groups, denoted by a two-tailed p-value of less than 0.05, but did not specify which groups 
were significantly different. In the instances where the Kruskal-Wallis test identified a 
significant difference among groups, the Mann-Whitney test was used to compare two groups at 
a time, in order to identify the specific groups that were significantly different. 
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Figure 6 Flow-chart describing strategy for statistical analyses. Data sets were tested for 
normality using the Shapiro-Wilk test. All data sets did not follow a normal distribution, 
therefore, non-parametric analyses were used. For continuous data that was represented as a 
boxplot, the Tukey method was used to identify outliers in each data set, and outliers were 
excluded prior to further statistical analyses. For categorical data, the 3x2 Fisher’s exact test was 
used. Significance was defined as having a two-tailed p-value of less than 0.05. NT = non-
tumour, T = tumour, CN = copy number, exp = expression, NS = never-smoker, S = smoker. 
Bold arrows indicate which statistical tests were used in this study.  
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Chapter 3  
3 Experimental Validation 
Before carrying out RBM5 gene copy number analyses, it was necessary to establish that the 
HSN cohort was representative of those previously presented in the literature 29,40, then 
determine the validity of the experimental procedures used in this study, including the 
confirmation of a normal 2n copy number in the BEAS-2B control cell line, the suitability of the 
qPCR primers and the suitability of the reference genes. Firstly, RBM5 mRNA expression in the 
HSN cohort was examined to confirm that RBM5 expression decreased in NSCLC tumours, 
compared to adjacent non-tumour tissue. Since the objective of this study was to determine if the 
previously noted significantly decreased levels of RBM5 expression in NSCLCs from smokers 40 
correlated with RBM5 deletion, it was crucial to confirm that the HSN cohort had significantly 
decreased RBM5 expression levels 29,40. Secondly, RBM5 gene copy number in the BEAS-2B 
cell line was compared to RBM5 gene copy number in patient samples and cell lines to confirm 
that the BEAS-2B cell line contained two copies of RBM5, and was, therefore, a suitable control 
sample. Thirdly, all primer pairs, for both DNA and RNA qPCR assays, test genes and reference 
genes, were examined to confirm that primers were both efficient and specific. Both efficiency 
and specificity of primers were required for precision and reproducibility when conducting qPCR 
analyses 112. Lastly, the reference genes, for both DNA and RNA analyses, were examined to 
confirm stable expression between non-tumour and tumour tissue, and between samples from 
smokers and never-smokers. Stable expression of reference genes was required for accurate 
normalization when RBM5 gene copy number and mRNA expression were calculated 91,93,113. 
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3.1 Cohort Validation 
Before analyzing RBM5 copy number in the patient samples, it was important to show that the 
HSN cohort was representative of those already described in the literature, with reduced RBM5 
expression occurring in tumour, compared to non-tumour, samples 29,40. To determine if our 
model was representative, we examined RBM5 mRNA expression in NSCLC tumour and 
adjacent non-tumour tissue from 53 patients, 39 and 14 of which were diagnosed with ADC and 
SqCC, respectively. For each patient sample (non-tumour or tumour), we obtained expression 
values from six technical replicates. Expression values per sample were averaged, excluding any 
within-sample outlier identified by the Grubb’s test. All non-tumour or tumour RBM5 
expression values were then graphed, excluding any outliers identified using the Tukey method. 
Using the Shapiro-Wilk normality test, the normalized RBM5 expression values in the non-
tumour data set and the tumour data set were found to not follow a normal distribution. Since the 
non-tumour and tumour samples were paired, a Wilcoxon signed-rank test was used to identify if 
RBM5 expression was significantly decreased in NSCLC tumours, compared to normal adjacent 
lung tissue.  
The grouped non-tumour and tumour boxplots with statistical outcomes are presented in Figure 
7. Expression results from patients diagnosed with both ADC and SqCC were combined, to 
represent all patients diagnosed with NSCLC. Comparing non-tumour and tumour RNA, it was 
shown that RBM5 expression in NSCLC tumours was significantly downregulated (Figure 7 A). 
ADC and SqCC were then examined separately, to confirm that RBM5 was downregulated in 
both NSCLC subtypes. Indeed, RBM5 expression decreased significantly in both ADC (Figure 7 
B) and SqCC (Figure 7 C). Therefore, the HSN cohort was a suitable model for the examination 
of mechanisms contributing to RBM5 downregulation in the lung cancers of smokers. 
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Figure 7 Confirmation of RBM5 downregulation in NSCLC tumours. Wilcoxon signed-rank 
tests were used to confirm that RBM5 mRNA expression decreased significantly in (A) NSCLC, 
(B) ADC and (C) SqCC tumours, compared to adjacent normal lung tissue. *p<0.05, 
****p<0.0001.  
3.2 Control Sample Validation 
The BEAS-2B cell line was chosen as a control sample for this study, since it was expected to 
retain a normal (2n) RBM5 copy number, because it is a “normal” non-tumorigenic cell line 36. 
Before commencing RBM5 gene copy number analyses on the HSN test samples, it was 
necessary to confirm that the BEAS-2B cell line indeed retained a normal two copies of the 
RBM5 gene. RBM5 gene copy number in the BEAS-2B cell line was compared to the GLC20 
SCLC cell line and the BT-474 breast cancer cell line, and also to two paired non-tumour and 
SCLC tumour samples. As anticipated, the GLC20 cell line, which has a homozygous deletion of 
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RBM5, did not amplify any RBM5 DNA by qPCR, and demonstrated a calculated RBM5 copy 
number of zero, when compared to the BEAS-2B cell line 16,39 (Figure 8). Since the BT-474 cell 
line does not harbour any alterations on the short arm of chromosome 3 (ATCC, catalog number: 
HTB-20), it was anticipated that the BT-474 cell line would retain a normal (2n) RBM5 copy 
number. BEAS-2B and BT-474 cell lines amplified identical quantities of RBM5 DNA, by 
qPCR, indicating that both cell lines retained two copies of RBM5. The OTB samples were 
previously shown to have a 50% reduction of RBM5 mRNA expression in SCLC tumours, 
compared to adjacent non-tumour samples, suggesting a loss of one RBM5 allele in both tumour 
samples 16. As anticipated, both non-tumour samples amplified similar quantities of RBM5 DNA 
as the BEAS-2B cell line, while both SCLC tumours amplified only half the amount of RBM5 
DNA. These results suggested that both non-tumour samples retained two copies of RBM5, while  
 
Figure 8 Validation of RBM5 gene copy number in the BEAS-2B cell line. RBM5 gene copy 
number in the BEAS-2B cell line was compared to RBM5 gene copy number in two cell lines 
(GLC20 and BT-474) and two paired non-tumour and tumour samples (Hamilton and Ottawa NT 
and T). NT = non-tumour, T = tumour. 
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the SCLC tumour samples only retained one copy of RBM5. Taking these results as a whole, the 
BEAS-2B cell line was confirmed to be a reliable comparator for the calculation of RBM5 copy 
number in various test samples. 
3.3 Primer Validation 
Before commencing with qPCR analyses, all primer pairs were validated to ensure that the 
chosen primers were efficient and specific 112. Amplification efficiency describes how efficiently 
the PCR products doubled after each successive cycle, while specificity refers to the degree of 
uniqueness of primer sequence recognition. 
With regards to primer efficiency, ideally, amplification efficiency should be close to 100%, as 
described by a standard curve slope of -3.32 100. In order to accurately interpret the efficiency of 
the primers, it is necessary that the data points on the standard curve are amplified at a linear 
rate, as demonstrated by a correlation coefficient (R2) value close to 1 100. Due to both inter- and 
intra-assay variability, obtaining an efficiency of 100% is not always possible. Generally, 
standard curves result in efficiency values between 1.6 and over 2, corresponding to efficiencies 
of 60% to over 100% 114,115. Efficiency values can fluctuate because of variability in estimated 
baseline fluorescence, contaminating Taq inhibitors, suboptimal annealing temperatures, 
amplicon secondary structures and poorly designed primers 116,117. As such, the literature 
strongly recommends an efficiency-corrected mathematical model, such as the Pfaffl method, for 
the interpretation of data with any fluctuation in efficiencies 114.  
With regards to primer specificity, primers were validated to confirm that one specific PCR 
product was amplified. Specificity was confirmed through melt-curve analyses, where the 
dissociation of double-stranded DNA PCR product should result in a single, sharp peak 100.  
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3.3.1 Primers for DNA Copy Number Analysis 
RBM5, PUM1 and RPLP0 primers were used for RBM5 copy number analyses by qPCR. 
Representative standard curves, efficiency values, and melt-curves are displayed in Figure 9. A 
total of 115 assays were completed for this study, and all standard curve efficiencies were above 
60%. Average RBM5 efficiency values fluctuated around 73.23%, while average PUM1 and 
RPLP0 efficiency values were 103.16% and 102.90%, respectively. Since RBM5 PCR products 
resulted in efficiency values below 100%, it was important to use an efficiency-corrected 
method, such as the Pfaffl method, for quantifying RBM5 expression 114. Because the primers 
were specific for one gene, and the PCR product was amplified at a linear rate, it was confirmed 
that the primer pairs were acceptable for subsequent RBM5 copy number analyses using an 
efficiency-corrected comparative Ct method. 
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Figure 9 Confirmation of efficiency, linearity and specificity of DNA primers. (A) RBM5, 
(B) PUM1 and (C) RPLP0 primer pairs were assessed. (i) Efficiency, E, and linearity, R2, were 
determined using standard curves of five BEAS-2B DNA dilutions between 100 ng and 6.25 ng, 
with technical triplicates. (ii) Specificity of primer pairs was determined using melt curves with 
dissociation temperatures between 65°C and 95°C. 
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3.3.2 Primers for RNA Expression Analysis 
RBM5, RPLP0 and ACTB primers were used for RBM5 mRNA expression analyses by qPCR. 
Representative standard curves and melt curves for each primer pair are displayed in Figure 10. 
The RBM5 primers, which were distinct from the primers used for gene copy number analysis, 
were used previously in the Sutherland lab, and the primer efficiency was confirmed 103. The 
previous validation of RBM5 primers resulted in an efficiency of 95%, using dilutions of H9c2 
cDNA, derived from rat myoblasts 103. In this study, a total of 65 assays were performed, and the 
average efficiency of RBM5 primers was 104.30%. This efficiency percentage was close to the 
ideal 100%, confirming that RBM5 PCR products were doubling with each successive cycle 100. 
The RPLP0 primers, which were also distinct from the primers used for gene copy number 
analysis, were generated from published primer sequences 89. In the Gresner et al. study, the 
reported efficiency of the primers was 101.3% 89. In our study, however, the average efficiency 
was 113.89% for these RPLP0 primers. It was noted that the Gresner et al. study used an 
annealing temperature of 57°C, whereas this study used a slightly higher melting temperature of 
60°C, which can affect the efficiency of the primers and result in the observed differences 89,117. 
The ACTB primers that were used in this study were also obtained from the literature 93. In the 
Radonic et al. study, the ACTB primers had an efficiency percentage of 99% 93. In our study, 
however, the efficiency of the primers was higher, at an average of 123.29%. Once again, 
differences in annealing temperatures were noted. The Radonic et al. study used an annealing 
and extension temperature of 67°C, whereas this study used an annealing temperature of 60°C 
and an extension temperature of 72°C, which may have influenced the observed changes in 
primer efficiency 93,117. Since reference gene primer efficiencies fluctuated at values slightly 
higher than 100%, it was important to use the efficiency-corrected Pfaffl method for all 
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Figure 10 Confirmation of efficiency, linearity and specificity of RNA primers. (A) RBM5, 
(B) RPLP0 and (C) ACTB primer pairs were assessed. (i) Efficiency, E, and linearity, R2, were 
determined using standard curves of five BEAS-2B cDNA dilutions between 1:1 and 1:625, with 
technical duplicate. (ii) Specificity of primer pairs was determined using melt curves with 
dissociation temperatures between 65°C and 95°C. 
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subsequent RBM5 expression calculations 114. Each primer pair produced one specific gene 
product that amplified at a linear rate, confirming that the primers chosen for RBM5 expression 
analyses were acceptable. 
3.4 Reference Gene Validation 
In qPCR analyses, normalizing to a reference gene is essential for eliminating variability in DNA 
and cDNA quantity or quality 89,91,93. As such, it is important to confirm that reference genes do 
not change in different tissue types or under different experimental conditions 92. To be certain 
that RBM5 gene copy number and RBM5 expression were accurately quantified by qPCR, 
references genes for both DNA and RNA analyses were validated. To validate the reference 
genes, it was necessary to confirm that the amount of PUM1 and RPLP0 DNA, as well as the 
expression of RPLP0 and ACTB, did not change between the two groups being compared (i.e. 
non-tumour vs tumour, and smoker vs never-smokers). Validation of each reference gene was 
carried out by comparing Ct values, and also by examining relative changes in DNA or RNA 
quantities. 
3.4.1 Reference gene quantities did not change between non-tumour and 
tumour DNA or RNA 
First, changes in the quantities of PUM1 and RPLP0 DNA were compared between non-tumour 
and tumour tissue. For this analysis, data from paired non-tumour and tumour samples, obtained 
from 65 patients, were used. The first analysis involved the comparison of mean Ct values. 
Distributions of raw Ct values have been used throughout the literature to validate reference 
genes 89,91. If Ct values were equivalent, it was assumed that reference gene expression was also 
equivalent. For each DNA sample, Ct values from six technical replicates were averaged. Any 
outlier within each of the six technical replicates was identified using the Grubb’s test, which is 
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only capable of identifying one outlier. If an outlier were detected, it was removed from the 
calculation of the mean Ct value for that particular sample. Mean Ct values from non-tumour and 
tumour tissue from each of the 65 patients were then graphed using boxplots (Figure 11 Ai). 
Outliers within each group were identified using the Tukey method, and excluded prior to 
statistical analyses. The Shapiro-Wilk test was performed to examine the distribution of data. 
One of the groups did not follow a normal distribution, and, as such, non-parametric analyses 
were used. Since the non-tumour and tumour DNA were obtained from the same patients, and 
therefore paired, a Wilcoxon signed-rank test was performed to identify statistically significant 
differences in reference gene Ct values between non-tumour and tumour DNA. It was 
determined that Ct values for each reference gene did not change between non-tumour and 
tumour DNA, confirming that the quantities of reference gene DNA was unlikely to be altered in 
the different tissue types. 
Since Ct distributions only provide a rough estimate of amplification changes, a secondary 
analysis was recommended to confirm that the quantities of reference gene DNA did not change 
between non-tumour and tumour tissue 91. The second analysis examined the quantity of 
reference gene in the tumour, relative to the non-tumour. DNA from the same 65 patients was 
also used in this analysis. The quantity of each reference gene was calculated using the relative 
standard curve quantification method, using the formula log 10[(Ct reference gene – y-intercept)/(-slope)], 
where the y-intercept and slope values were taken from the PUM1 and RPLP0 standard curves 
118,119. This calculation was performed on each of the six technical replicates. Outliers in each of 
the six technical replicates were identified using the Grubb’s method. For each patient sample, 
the quantity of reference gene was averaged from the six technical replicates, excluding any 
outliers. To demonstrate the suitability of using the two reference genes together, the geometric 
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mean of the quantities of both PUM1 and RPLP0 was also calculated. The mean quantity of 
reference gene in the tumour DNA was then normalized to the mean quantity of reference gene 
in the non-tumour DNA, for each patient. If the quantities of reference gene DNA remained 
constant between both tissue types, the normalized value was close to 1. The normalized values 
were then graphed using boxplots (Figure 11 Aii). Outliers were identified using the Tukey 
method, and excluded. As demonstrated by Figure 11 Aii, the quantities of individual reference 
genes, and the geometric mean of the reference genes, remained constant in most patient 
samples, as demonstrated by normalized values that are close to 1. Taking both the Ct analyses 
and the relative quantification analyses as a whole, it was confirmed that the amount of PUM1 
and RPLP0 DNA did not change between non-tumour and tumour tissue, indicating that both 
genes are suitable reference genes for calculation of RBM5 gene copy number. 
The same two analyses were also completed to confirm the suitability of RPLP0 and ACTB as 
reference genes for RBM5 mRNA expression analyses. First the distribution of Ct values was 
compared between non-tumour and tumour RNA from 53 patients. For each sample, we obtained 
Ct values from six technical replicates. The mean Ct value was calculated for each sample, 
averaging the six technical replicates and excluding any outliers identified by the Grubb’s test. 
Mean Ct values were then graphed as boxplots (Figure 11 Bi). Outliers were identified using the 
Tukey method, and removed prior to statistical analyses. As per the Shapiro-Wilk test, the data 
sets did not follow a normal distribution, and, as such, non-parametric statistical analyses were 
completed. Since the non-tumour and tumour pairs were obtained from the same patients, a 
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Figure 11 Analysis of changes in reference gene Ct values and the corresponding changes in 
reference gene quantities. Reference genes were compared between non-tumour and tumour in 
(A) DNA from 65 patients and (B) RNA from 53 patients. (i) Mean Ct values of each reference 
gene were compared using the Wilcoxon singed-rank test. ***p<0.001,****p<0.0001. (ii) 
Individual reference gene quantities, and the geometric mean of reference gene quantities, in 
tumour tissue relative to non-tumour tissue, was compared to confirm relative values close to 1, 
representing no changes or minimal changes in DNA or RNA quantities. 
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paired Wilcoxon signed-rank test was used to identify statistically significant differences 
between non-tumour and tumour Ct values. Both reference genes resulted in significant changes 
in Ct values between non-tumour and tumour RNA. For RPLP0, non-tumour and tumour RNA 
demonstrated a difference in median Ct values of approximately 1.5 cycles, while ACTB 
displayed a difference in median Ct values of approximately one cycle. In the publication from 
Gresner et al., where the RPLP0 primers were found, the median Ct values demonstrated a 
difference of approximately one cycle between non-tumour and tumour, where the tumour had 
the lower Ct value, similar to what was observed in this study 89. The publication stated that the 
difference in median Ct values was not large enough to assume changes in expression 89. 
Although the Radonic et al. study, from which the ACTB primers were obtained, did not analyze 
differences in Ct values between non-tumour and tumour RNA, we can assume the same 
principle applies, in which a difference of one Ct is not enough to permit changes in ACTB 
expression 93. As such, further analyses were required to confirm that expression of RPLP0 and 
ACTB did not change, despite significant changes in Ct values. 
Expression of RPLP0 and ACTB was compared in tumour RNA relative to non-tumour RNA in 
the 53 patients from whom we obtained paired non-tumour and tumour RNA. Using the Ct 
values from each of the six technical replicates from the patient samples, expression of RPLP0 
and ACTB was calculated using the relative standard curve quantification method described 
above 118,119. The calculation was performed on each of the six technical replicates, and then the 
average of the six technical replicates was taken, excluding any outliers identified by the Grubb’s 
test. To examine the suitability of using the two reference genes together, the geometric mean of 
the expression of RPLP0 and ACTB was also calculated. Relative expression values for RPLP0, 
ACTB, and the geometric mean of the two reference genes, were calculated by normalizing 
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expression values in the tumour RNA relative to the non-tumour RNA (Figure 11 Bii). The mean 
normalized expression values were 0.84, 0.88 and 0.86 for RPLP0, ACTB, and the geometric 
mean of the two reference genes, respectively. Although there appeared to be slightly less 
expression of both of the reference genes in tumour RNA, this slight difference was considered 
acceptable for normalization purposes. In reference to the literature, median fold-changes of less 
than 1.7 and mean fold-changes of less than 1.8 have been reported as acceptable 89,91. Since the 
changes in expression of the reference genes, in this study, are less than the reported values in 
the literature, it was confirmed that RPLP0 and ACTB were suitable reference genes for the 
normalization of RBM5 qPCR data. 
3.4.2 Reference gene quantities did not change between smoker and never-
smoker DNA 
As previously mentioned, the act of smoking can inflict DNA damage, causing aberrant lesions, 
including allelic loss 65,66,71. Since one of the intentions of this study was to compare RBM5 gene 
copy number in smokers to never-smokers, it was necessary to ensure that the reference genes 
did not change with tobacco smoke exposure, as allelic loss of reference genes would not allow 
for accurate quantification of RBM5 gene copy number. To examine this, Ct values of PUM1 and 
RPLP0 were compared between never-smokers and a subset of smokers diagnosed with NSCLC. 
As the cohort contained only five never-smokers diagnosed with NSCLC, the never-smokers 
were compared to a small subset of smokers, so that the sample sizes would be similar. The 
subset of smokers included eight patients diagnosed with NSCLC. These eight patients were 
chosen specifically because they had the most tobacco smoke exposure, measured in pack-years. 
It was assumed that the patients with the most tobacco smoke exposure were the patients who 
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were most likely to exhibit aberrant DNA lesions in reference genes, related to smoking. The 
number of pack-years in the eight patients ranged between 60 and 130.  
For each patient sample (non-tumour and tumour), Ct values from six technical replicates were 
used. The average Ct value was calculated for each patient sample, excluding any outliers 
identified by the Grubb’s test. Average Ct values from the five never-smokers and the eight 
smokers were then graphed, using a boxplot (Figure 12). Outliers were identified using the 
Tukey method, and excluded prior to statistical analyses. Since the data sets did not follow a 
normal distribution, and samples were not paired, a Mann-Whitney test was used to determine if 
the difference in mean Ct values between never-smokers and smokers was statistically 
significant. As demonstrated in Figure 12, mean Ct values of both PUM1 and RPLP0 did not 
change significantly between never-smokers and smokers, in both non-tumour DNA (Figure 12 
A) and tumour DNA (Figure 12 B), indicating that the DNA for both reference genes was 
unlikely to be altered by smoking. Through this reference gene validation, it was confirmed that 
PUM1 and RPLP0 were suitable reference genes for normalizing RBM5 gene copy number 
values, in both never-smokers and smokers. 
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Figure 12 Comparative analyses of reference genes in never-smokers and smokers. Mann-
Whitney tests were used to examine the difference in mean Ct values for PUM1 and RPLP0 
reference genes between never-smokers and smokers in (A) non-tumour and (B) tumour DNA. 
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Chapter 4  
4 RBM5 Gene Copy Number Analysis 
The objective of this study was to determine if the significantly decreased levels of RBM5 
expression in the NSCLCs of smokers was related to RBM5 deletion. To examine this, RBM5 
copy number was quantified in all patient DNA samples from the HSN cohort. Using these data, 
the number of patients that demonstrated RBM5 deletions was determined. Next, RBM5 copy 
number was compared between non-tumour and NSCLC tumour DNA, to determine if RBM5 
gene copy number was significantly decreased in tumours. Following this, statistical analyses 
were carried out to determine if RBM5 gene copy number was related to the level of RBM5 
mRNA expression in both non-tumour and tumour tissue. Finally, RBM5 gene copy number was 
compared in never-smokers and smokers, to determine if RBM5 gene copy number was 
associated with tobacco smoke exposure. After a complete analysis of the HSN cohort, this study 
was broadened and similar analyses were repeated using SCLC tumour DNA obtained from a 
collaborator in Slovakia. 
4.1 HSN Cohort Study 
4.1.1 RBM5 deletions were detected in a small percentage of patients 
Since RBM5 mRNA was significantly downregulated in NSCLC tumours, compared to normal 
lung tissue, it was expected that at least one copy of RBM5 would be deleted in tumour DNA, 
contributing to the observed downregulation at the mRNA level. To test this, RBM5 copy 
number was examined in the non-tumour and tumour DNA from 65 patients diagnosed with 
ADC or SqCC, from whom paired samples were obtained. The quantified RBM5 copy numbers 
were averaged from six technical replicates per patient sample, excluding any outliers identified 
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by the Grubb’s test. The average copy numbers in this group ranged between 0.851 and 3.142. 
Since quantified copy numbers were not integers (i.e. 1, 2 and 3), copy numbers were interpreted 
according to theoretical boundaries between copy numbers of 1, 2 and 3. These theoretical 
boundaries were determined using the geometric means of the integer copy number values, as 
suggested in an article describing accurate copy number profiling using qPCR 100. The geometric 
mean of copy numbers 1 and 2 was 1.414, while the geometric mean of copy numbers 2 and 3 
was 2.449. Using these theoretical boundaries, copy number results between 1.414 and 2.449 
were normal (2n), while results below 1.414 were interpreted as a deletion (1n), and results 
above 2.449 were interpreted as a duplication (3n+) 100.  
Using these integer copy number data, it was determined that more than one-fifth (21.6%) of the 
patients harboured RBM5 deletions in tumour DNA (Table 4). Of the 14 patients that exhibited 
RBM5 deletions in tumour DNA, seven patients also demonstrated RBM5 deletions in non-
tumour DNA. As some smokers are known to harbour 3p21.3 deletions in normal bronchial 
epithelium, it was not surprising that all seven of these patients were either current or former 
smokers 47. Interestingly, there were eight patients who demonstrated RBM5 deletions in non-
tumour DNA, while tumour DNA was unaltered. All eight of these patients were either current 
or former smokers; therefore, 3p21.3 deletions in the non-tumour tissue could be anticipated 47. 
The fact that the corresponding tumour DNA in these patients did not harbour any RBM5 
deletions was, however, unexpected. It was originally suspected that, perhaps, these patients 
might have been smokers with minimal pack-years who developed a lung cancer unrelated to 
smoking, such as an EGFR-positive or ALK-positive adenocarcinoma 81. This theory, however, 
was proven to be incorrect. The eight patients were smokers with between 15 and 64 pack-years, 
smoking an average of approximately one pack per day. Three of the patients were diagnosed 
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with SqCC, a type of lung cancer that is generally diagnosed in heavy smokers, while the 
remaining five were diagnosed with ADC, none of which were EGFR-positive or ALK-positive 
70,120. Looking at additional pathological parameters, patterns driving this observation, of 
decreased copy number in the non-tumour samples only, were not apparent. 
Table 4 RBM5 copy number results for 65 paired samples from patients diagnosed with 
ADC and SqCC 
RBM5 Copy Number 
N value 
(total 65) 
Percent 
(%) 
N value 
Smokers 
(total 60) 
Percent 
(%) 
N value 
Never 
Smokers 
(total 5) 
Percent 
(%) 
Deletions (1n) 22 33.8 20 33.3 2 40.0 
T only a 7 10.8 5 8.3 2 40.0 
NT and T 7 10.8 7 11.7 0 0.0 
NT only 8 12.3 8 13.3 0 0.0 
Duplications (3n+) 5 7.7 4 6.7 1 20.0 
T only 3 4.6 2 3.3 1 20.0 
NT and T 1 1.5 1 1.7 0 0.0 
NT only 1 1.5 1 1.7 0 0.0 
Normal (2n) 38 58.5 36 60.0 2 40.0 
a with the “only” designation, the corresponding non-tumour or tumour remained 2n 
In some instances, RBM5 duplications were observed. Tumours harboured RBM5 duplications in 
6.1% of patients. Three of these patients displayed duplications in the tumour DNA only, while 
only one patient demonstrated RBM5 duplications in both non-tumour and tumour DNA. 
Unexpectedly, one patient displayed a duplication of RBM5 in the non-tumour DNA only, 
retaining a normal (2n) copy number in the tumour DNA. Pathological parameters were 
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examined to determine if the patients harbouring RBM5 duplications had any similarities that 
might explain these results, but there were not any outstanding similarities. 
In regards to smoking status, 60 patients were either current or former smokers, while only five 
were never-smokers. In the smokers, 60% had a 2n RBM5 copy number, 33.3% had deletions, 
and 6.7% had amplifications. In the never-smokers, three out of five RBM5 copy number 
alterations in tumour DNA: two of these patients displayed RBM5 deletions in tumour DNA, 
while one patient demonstrated a duplication of RBM5 in tumour DNA. The most important 
observation noted amongst the five never-smokers was the fact that none of these patients 
harboured RBM5 alterations in non-tumour DNA, suggesting that RBM5 deletions and 
duplications observed in non-tumour DNA are strictly smoking-related events. Unfortunately, 
the discrepancy in sample sizes made it impossible to attach statistical significance to these 
finding. 
4.1.2 RBM5 gene copy number was not significantly reduced in NSCLC 
tumour DNA 
As described in Chapter 3, Section 3.1, a significant downregulation of RBM5 mRNA was 
observed in NSCLC tumours. It was, therefore, anticipated that RBM5 gene copy number in 
tumours would also be significantly decreased, demonstrating that RBM5 downregulation in 
NSCLC was caused by deletion of at least one copy of the RBM5 gene. To determine 
significance, DNA data from ADC and SqCC patients were first grouped together, for analysis, 
so that RBM5 copy number could be examined in NSCLC as a whole. Data were then analyzed 
separately, so that any possible differences in RBM5 copy numbers related to specific NSCLC 
subtypes could be identified. Normality testing with the Shapiro-Wilk test determined that all 
data sets did not follow a normal distribution, allowing for non-parametric statistical tests. A 3x2 
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Fisher’s exact test was used to examine significance differences in RBM5 copy number between 
non-tumour and tumour DNA in patients diagnosed with NSCLC (Figure 13 A), ADC (Figure 13 
B) and SqCC (Figure 13 C). As demonstrated in Figure 13, RBM5 copy number was not 
significantly reduced in tumour DNA, compared to non-tumour DNA, in NSCLC, and in both 
ADC and SqCC subtypes. 
 
 
Figure 13 A comparison of RBM5 copy number in non-tumour and NSCLC tumour DNA. 
A 3x2 Fisher’s exact test was used to compare RBM5 gene copy number in non-tumour and 
tumour DNA from patients diagnosed with (A) NSCLC, (B) ADC and (C) SqCC. 
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4.1.3 RBM5 gene copy number was related to RBM5 mRNA expression in the 
non-tumour tissue, but not the tumour tissue 
To determine if the deletion events were related to loss of RBM5 mRNA expression, in the same 
tissue sample, statistical analyses were carried out. For this analysis, 53 paired DNA and RNA 
samples were utilized from both non-tumour and tumour tissue. The relationship between RBM5 
gene copy number and average normalized RBM5 mRNA expression levels were analysed using 
a Kruskal-Wallis test, since the RNA data sets did not follow a normal distribution. Boxplots 
representing RBM5 expression levels, obtained from tissue samples with varying RBM5 copy 
numbers, are presented in Figure 14 A. Outliers were identified using the Tukey method, and 
excluded prior to statistical analyses. In the non-tumour tissue (Figure 14 Ai), a significant 
difference between RBM5 copy number and RBM5 mRNA expression levels was observed using 
the Kruskal-Wallis test. Since the Kruskal-Wallis test could not specify which groups were 
significantly different, the non-parametric Mann-Whitney test was used to compare each of the 
groups separately. It was determined that there was a significant difference in RBM5 mRNA 
expression between patients with RBM5 copy numbers of 1n and 2n. Non-tumour tissue with a 
RBM5 copy number of 1n demonstrated significantly reduced RBM5 mRNA levels, compared to 
non-tumour tissue with a RBM5 copy number of 2n. In the tumour tissue (Figure 14 Aii), there 
were not any significant differences in RBM5 expression between tumours of varying RBM5 
copy numbers. Taking these data as a whole, it appeared as though deletion of RBM5 influenced 
loss of RBM5 expression in non-tumour tissue, but deletion of RBM5 in tumour tissue did not 
influence loss of RBM5 expression, since expression was reduced in majority of the samples, 
even in those with normal (2n) copy numbers and duplications. 
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Next, RBM5 mRNA expression was characterized in the groups harbouring various deletion 
events, and in the patients with normal (2n) copy numbers, using the categories presented in 
Table 4. Of the 65 patients that were included in Table 4, we obtained paired RNA samples from 
53 of those patients. Non-tumour and tumour RBM5 mRNA expression values in each respective 
category were presented as boxplots (Figure 14 B). Outliers were identified using the Tukey 
method, and excluded prior to statistical analyses. The Shapiro-Wilk test determined that the 
small data sets did not follow a normal distribution, and, as such, non-parametric statistical 
analyses were used. Since the non-tumour and tumour mRNA samples were from the same 
patient, a Wilcoxon signed-rank test was used to determine if there was a statistically significant 
difference in RBM5 expression between non-tumour and tumour pairs in each of the respective 
categories. 
Of the seven patients that exhibited a deletion in the tumour only, we obtained six paired RNA 
samples. All six tumours showed reduced RBM5 mRNA expression levels that were 
approximately half of what was observed in the non-tumour tissue (Figure 14 Bi). This result 
was anticipated, because, based on the hypothesis of this study, the non-tumour tissue that 
retained a normal (2n) RBM5 copy number would express normal levels of RBM5, while the 
tumour tissue that exhibited RBM5 deletions would express reduced levels of RBM5, reflective 
of loss of one allele.  
Next, of the seven patients that exhibited RBM5 deletions in both non-tumour and tumour tissue, 
paired RNA was obtained from six of those patients. As anticipated, RBM5 expression was 
reduced in both tissue types (Figure 14 Bii), suggesting that RBM5 deletions influenced RBM5 
mRNA expression levels. 
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Figure 14 Associations between RBM5 copy number and mRNA expression. (A) Boxplots 
were constructed to demonstrate the relationship between RBM5 copy number and RBM5 
mRNA expression in (i) non-tumour and (ii) tumour tissue. The Kruskal-Wallis test was used to 
evaluate the relationship between RBM5 copy number and RBM5 mRNA expression values in 
all data sets. The Mann-Whitney test determined significant differences between each copy 
number group. *p<0.05. (B) RBM5 mRNA expression levels in patients with an RBM5 gene 
copy number of 1 in (i) tumour only, (ii) non-tumour and tumour, and (iii) non-tumour only. (iv) 
RBM5 mRNA expression in patients with an RBM5 gene copy number of 2. Statistically 
significant differences between RBM5 expression values in non-tumour and tumour tissue were 
evaluated using the Wilcoxon signed-rank test. ****p<0.0001. 
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From the eight patients that harboured deletions in the non-tumour tissue, but not the tumour 
tissue, seven paired RNA samples were obtained. As demonstrated by Figure 14 Biii, most of the 
seven patients demonstrated loss of RBM5 mRNA expression in both non-tumour and tumour 
tissue. This result suggests that, although deletion of RBM5 may contribute to decreased RBM5 
expression in non-tumour tissue, deletion of RBM5 was not required for the downregulation of 
RBM5 in tumour tissue. Supporting this observation, the patients that demonstrated normal (2n) 
RBM5 copy numbers, in non-tumour and tumour tissue, demonstrated significantly reduced 
RBM5 expression levels in tumour tissue, compared to non-tumour tissue (Figure 14 Biv). These 
results suggested that there was more than one mechanism of RBM5 downregulation in NSCLC 
tumours. 
4.1.4 Smokers have substantially reduced RBM5 copy numbers in non-tumour 
DNA, compared to never-smokers 
To examine if deletion of RBM5 was associated with smoking, RBM5 gene copy number was 
compared in smokers and never-smokers, in both non-tumour and tumour DNA. For this 
analysis, 60 paired non-tumour and tumour DNA specimens from smokers, as well as five paired 
non-tumour and tumour DNA specimens from never-smokers were used. The lack of available 
DNA specimens from never-smokers caused a substantial discrepancy in sample sizes between 
smokers and never-smokers, and, therefore, limited statistical power for this analysis. The 
number of patients in each RBM5 gene copy number category, from smokers and never-smokers, 
was graphed as bar graphs for both non-tumour (Figure 15 A) and tumour (Figure 15 B) tissue. 
The never-smokers did not follow a normal distribution, as per the Shapiro-Wilk test for 
normality, and so non-parametric statistical analyses were carried out. A 3x2 Fisher’s exact test 
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was used to determine if there was a statistically significant difference in RBM5 gene copy 
number between smokers and never-smokers, in both non-tumour and tumour tissue. 
In non-tumour DNA, although not significant, only smokers demonstrated RBM5 loss (Figure 15 
A). As anticipated, all five never-smokers retained a normal (2n) RBM5 gene copy number in 
non-tumour tissue. The reduction in RBM5 gene copy number in the non-tumour DNA of 
smokers was anticipated, as 3p21.3 deletions have been observed in the normal bronchial 
epithelium of smokers 47. These results suggest that RBM5 deletions in non-tumour DNA are 
dependent on tobacco smoke exposure.  
Despite the fact that substantial differences in RBM5 gene copy number, related to tobacco 
smoke exposure, were observed in non-tumour DNA, the same effect was not detected in tumour 
DNA. There were not any significant differences in RBM5 copy number between smokers and 
never-smokers (Figure 15 B). RBM5 copy numbers were more variable in the tumour tissue from 
never-smokers, compared to the adjacent non-tumour tissue. Two never-smokers displayed two 
copies of RBM5, while the remaining three presented deletions (n=2) or duplications (n=1), in 
tumour DNA. The fact that RBM5 deletions were observed in both smokers and never-smokers 
suggests that loss of one RBM5 allele in NSCLC may have occurred independent of tobacco 
smoke exposure.  
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Figure 15 A comparison of RBM5 copy number in smokers and never-smokers. A 3x2 
Fisher’s exact test was used to compare RBM5 gene copy numbers in (A) non-tumour and (B) 
tumour DNA from smokers and never-smokers. 
 
A.
B.
Non-tumour
RBM5 gene copy number
N
u
m
b
e
r 
o
f 
p
a
ti
e
n
ts
1n 2n 3n
0
10
20
30
40
50
Smoker
Never-smoker
Tumour
RBM5 gene copy number
N
u
m
b
e
r 
o
f 
p
a
ti
e
n
ts
1n 2n 3n
0
10
20
30
40
50
Smoker
Never-smoker
76 
 
4.2 Slovakian Cohort Study 
4.2.1 RBM5 deletions were detected in half of the SCLC tumours 
Through collaboration, tumour DNA was obtained from a Slovakian cohort, consisting of 44 
patients diagnosed with SCLC. It was anticipated that, since LOH at 3p21.3 is more common in 
SCLC than NSCLC, and RBM5 was shown to be homozygously deleted in three SCLC cell lines, 
RBM5 would be deleted more frequently in the SCLC tumour DNA, compared to the NSCLC 
tumour DNA 45-47. The quantified RBM5 copy numbers in the Slovakian cohort ranged between 
0.868 and 3.890. Once again, theoretical boundaries of 1.414 and 2.449 were used, as described 
previously, to distinguish normal copy number (2n) from deletions (1n) and duplications (3n+).  
As anticipated, RBM5 deletions were more frequent in the SCLC tumours, as 50.0% of patients 
demonstrated a loss of one RBM5 allele (Table 5).  The frequency of duplications observed in the 
SCLC cohort was similar to the frequency observed in the HSN NSCLC cohort. Furthermore, a 
large percentage (40.9%) of SCLC tumours retained both copies of the RBM5 gene. Paired non- 
tumour DNA was not available, and so it was impossible to directly compare copy numbers 
between non-tumour and tumour DNA. As such, it could not be determined if the greater 
frequency of deletions in SCLC tumours was significant. 
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Table 5 RBM5 copy number results for Slovakian SCLC tumour samples 
RBM5 Copy Number 
N value 
(total 44) 
Percent 
(%) 
N value 
Smokers 
(total 34) 
Percent 
(%) 
N value 
Never 
Smokers 
(total 8) 
Percent 
(%) 
Deletions (1n) 22 50.0 17 50.0 5 62.5 
Duplications (3n+) 4 9.1 4 11.8 0 0.0 
Normal (2n) 18 40.9 13 38.2 3 37.5 
*The smoking status of two patients was not obtained, and, therefore, these patients could not be included in either 
of the smoking status categories. 
 
4.2.2 RBM5 deletions in SCLC tumours were not related to smoking status 
Since smoking information linked to 42 of the 44 patient samples was received, it was possible 
to compare RBM5 copy number in smokers and never-smokers. In the Slovakian cohort, DNA 
from 34 smokers and 8 never smokers was obtained. The number of patients that fit into specific 
copy number categories were graphed as bar graphs, for both smokers and never-smokers. Since 
the data did not follow a normal distribution, as per the Shapiro-Wilk normality test, the non-
parametric 3x2 Fisher’s exact test was used to determine if there was a significant difference 
between the number of patients with RBM5 deletions in the smoking and non-smoking 
categories. Using this test, it was determined that there was not a statistically significant 
difference in RBM5 copy number between smokers and never smokers (Figure 16).  
The lack of significant differences in RBM5 copy number was apparent when examining the 
percentages of smokers and never-smokers in each of the copy number categories. Similar 
percentages of smokers and never-smokers retained two copies of RBM5, as 38.2% (13/34) of 
smokers and 37.5% (3/8) of never-smokers displayed normal (2n) RBM5 copy number values. 
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With respect to RBM5 deletions, 50% (17/34) of smokers and 62.5% of never-smokers (5/8) 
displayed loss of one RBM5 allele, further demonstrating RBM5 copy number similarities 
between smokers and never-smokers. The similar percentages of RBM5 deletions observed in 
both smokers and never-smokers indicated that RBM5 deletions in SCLC tumours were likely 
unrelated to tobacco smoke exposure.  
 
 
 
 
Figure 16 A comparison of RBM5 copy number in tumour DNA of smokers and never-
smokers. A 3x2 Fisher’s exact test was used to determine if mean RBM5 copy numbers in SCLC 
tumours were significantly different between smokers and never-smokers. 
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Chapter 5  
5 Discussion 
5.1 Experimental limitations and possible confounders 
5.1.1 Only one region of the RBM5 gene was used for copy number analyses 
The major experimental limitation of this study was the fact that only one region of the RBM5 
gene was analyzed for copy number alterations. In order to be certain that there was loss of one 
RBM5 allele, multiple primer pairs mapping to different regions of the RBM5 gene should have 
been used. If one whole RBM5 allele was deleted, then a copy number of one would be 
anticipated for all primer pairs. Alternatively, if different primer pairs, mapping to different 
regions of the RBM5 gene, resulted in different copy numbers, it would suggest that the RBM5 
gene was altered through other mechanisms, in very specific regions. For instance, primers may 
not hybridize to sequences of the gene that have been mutated, preventing amplification of DNA, 
even though the gene is intact. Additionally, deletions that do not comprise the whole gene have 
also been observed in cancer 56. Therefore, in order to accurately claim RBM5 allele loss, gene 
deletion should be confirmed at multiple sites using multiple primer pairs, or the data should be 
validated by another technique. Other techniques that can be used to analyse deletion of RBM5 
include fluorescence in situ hybridization and next-generation sequencing 121,122. 
5.1.2 Heterogeneity of crude tissue samples could have skewed RBM5 copy 
number results 
A second experimental limitation in this study was the fact that we were using crude tissue 
specimens containing heterogeneous cell types. It is estimated that approximately 50-75% of 
crude lung tumour biopsies consist of normal cells 123. These normal cells, which may not 
contain 3p21.3 deletions, have the ability to skew RBM5 copy number results, driving the data 
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towards a normal (2n) copy number. In fact, in this study, approximately half of the RBM5 copy 
numbers were calculated as decimal values between 1 and 2. This observation could be 
indicative of heterogeneous cell populations, in which tumour cells might have harboured RBM5 
deletions, but the presence of normal cells, containing normal (2n) RBM5 copy numbers, drove 
the calculated copy number towards a normal (2n) result. If this was the case, some DNA 
samples may have been improperly categorized as normal 124. This type of error would have 
prevented us from accurately quantifying RBM5 deletions, meaning that the frequency of RBM5 
deletions in tumours may be higher than what was observed in this study. For improved accuracy 
of copy number calculations, laser capture microdissection should be used to isolate homogenous 
tumour cells, prior to extracting DNA for copy number analyses 125. Utilization of this technique 
would allow for a more accurate representation of the tumour genome, eliminating interference 
from confounding DNA from heterogeneous cell types. 
Instances where RBM5 deletions were observed in the non-tumour, but not the tumour, can also 
be explained by tumour heterogeneity. Intratumour heterogeneity has been identified within 
primary tumours, as populations of distinct subclones that are diverse in DNA content and 
chromosomal imbalances have been described 126. In fact, one study estimated that eight or more 
independently altered clonal patches are present per cm2 of lung tumour 127. For the lung tissue 
used in this study, tiny pieces of non-tumour and tumour tissue, that were much less than 1 cm, 
constituted the 20 mg that was removed from the tissue specimens for simultaneous DNA, RNA 
and protein extraction, therefore, only representing a small number of clonal populations. 
Consequently, the subclonal population from which tumour DNA was obtained may not have 
been representative of a subclonal population that was derived from the altered non-tumour 
tissue. In fact, one study could not identify a clonal relationship between non-tumour and tumour 
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clonal patches present in the lungs of smokers, and the authors attributed this result to 
heterogeneity 128. In order to accurately describe RBM5 gene copy number in the NSCLC 
tumours used in this study, different sections of the tumour should have been analysed for 
alterations in copy number, to ensure that multiple subclonal populations were accounted for. 
5.1.3 The lack of available DNA samples from never-smokers limited 
statistical power 
One of the obvious experimental limitations in this study was the lack of available DNA from 
never-smokers. This experimental limitation is constant across many lung cancer studies. The 
problem with studying never-smokers with lung cancer, is the fact that never-smokers rarely 
develop lung cancer. As mentioned previously, only 15% of lung cancer diagnoses occur in 
never-smokers 65. As a result, it is very difficult to obtain the number of never-smoker samples 
necessary for statistical power. In this study, of the 103 patients from which tissue samples were 
obtained, only 80 patients had a diagnosis of either ADC or SqCC. Of these 80 patients, only six 
were never-smokers, which equates to only 7.5% of the NSCLC group. This means that the HSN 
cohort contained less never-smokers than expected from a typical population. To complicate 
matters even further, paired samples were received from five of the six never-smokers. In regards 
to our Slovakian cohort, eight out of 44 patients were never-smokers, accounting for 18.2% of 
the cohort. This percentage is actually higher than what would be expected, as, generally, SCLC 
in never-smokers is rare 75,76.  
G*Power 3.1 is a software that can compute the necessary sample size required for statistical 
power in a given study 129,130. This software was used to determine the number of smokers and 
never-smokers that would have been necessary to detect significant differences in the proportions 
of patients with RBM5 deletions. Using the G*Power 3.1 software, the appropriate sample size 
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calculator was chosen to examine proportions of two independent groups (smokers and never-
smokers), with the intention of analysing significant differences using the Fisher’s exact test. To 
use this calculator, the proportion of smokers with RMB5 deletions, the proportion of never-
smokers with RBM5 deletions, and the ratio of never-smokers to smokers, was required. The 
ideal error probability, power, and the selection of either a one- or two-tailed test were also 
required. The parameters chosen for the test included an error probability of 0.05, a power of 
0.95, and a two-tailed test. Using RBM5 copy number data from the non-tumours, the proportion 
of smokers with a RBM5 deletion was 0.25 (15/60), the proportion of never-smokers with a 
RBM5 deletion was 0 (0/5), and the ratio of never-smokers to smokers was 0.083 (5 never-
smokers/60 smokers). Using these values with the defined parameters, the G*Power 3.1 
calculator stated that at least 216 smokers and 18 never-smokers were necessary to detect a 
significant difference in the proportions of RBM5 deletions between never-smokers and smokers. 
Given these calculations, it is clear that this study did not have the sample size required to 
accurately detect significant differences in RBM5 copy number between never-smokers and 
smokers. 
5.1.4 Second-hand smoke exposure and occupational exposures could have 
confounded RBM5 copy number data 
As mentioned previously, second-hand smoke exposure accounts for approximately 1.6% of lung 
cancers 67. It was hypothesized that deletion of RBM5 was a tobacco smoke-related event, 
meaning that it was possible that second-hand smoke exposure could contribute to RBM5 
deletions. As all of the never-smokers diagnosed with NSCLC had between 18 and 64 years of 
second-hand smoke exposure, it is possible that the deletions observed in the tumours of never-
smokers were a product of second-hand smoke exposure. In the Slovakian cohort, tumour DNA 
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was obtained from eight never-smokers, five of which harboured RBM5 deletions. As we did not 
receive second-hand smoke exposure information, it is unknown whether RBM5 deletions were 
influenced by second-hand tobacco smoke exposure. Ideally, second-hand smoke exposure 
would be ruled out as a confounder by comparing RBM5 gene copy number in never-smokers 
with and without second-hand smoke exposure, if the DNA samples were available. 
Another possible confounder that could have contributed to deletion of RBM5 was occupational 
exposures to carcinogens, particularly in relation to mining and chromium processing. Mine 
work has been associated with a number of occupational hazards that could contribute to lung 
cancer including radon, asbestos, silica dust, diesel fumes and heavy metals 76. In the HSN 
cohort, 24 men and one woman documented that they had previously worked in a mine. To 
determine if mine work was a confounder, RBM5 gene copy number was compared between the 
24 men that worked in a mine to the remaining 31 men who had never worked in a mine. It was 
determined that there was not a significant difference in the mean RBM5 gene copy numbers of 
miners in the HSN cohort (data not shown), proving that mine exposure was not a confounder in 
the study of RBM5 copy numbers in the HSN cohort. The SCLC samples that were received 
from Slovakia were previously part of a study that examined chromium exposure and SCLC 
incidence. Chromium exposure has previously been shown to inflict DNA damage, contributing 
to lung cancer development 131. As information on which of the 44 SCLC patients had previous 
exposure to chromium was not received, chromium could not be ruled out as a confounder. Had 
this information been available, RBM5 gene copy number would have been compared between 
patients exposed to chromium and patients who were never exposed to chromium. 
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5.2 Gene deletion was not the primary mechanism of RBM5 
downregulation in NSCLC tumours 
Upon interpretation of the collective RBM5 gene copy number data, it was apparent that RBM5 
gene copy number was not significantly decreased in tumours. Due to the low frequency of 
deletion events that contrasted the high frequency of downregulation observed at the mRNA 
level, it was concluded that gene deletion was not the primary mechanism by which RBM5 was 
downregulated in NSCLC tumours. Since it has been demonstrated that TSGs in the common 
3p21.3 deletion region are downregulated by more than one mechanism, it is possible that the 
observed RBM5 deletions may be responsible for only a small percentage of the observed 
downregulation in NSCLC tumours. 
It was discovered that deletion of one RBM5 allele was much more frequent in the Sloviakian 
cohort, as 50.0% of the patients harboured a deletion. Non-tumour DNA from this cohort was not 
obtained, and non-tumour and tumour DNA could not be compared to determine if RBM5 gene 
copy number significantly decreased in this cohort. As the proportion of SCLC tumours 
exhibiting RBM5 deletions was more than double what was observed in the NSCLC tumours, it 
is possible that the greater frequency of deletions could have driven a significant difference, 
assuming that most non-tumour DNA was normal (2n). Normal RBM5 gene copy numbers, 
however, would not be expected in the non-tumour DNA from patients diagnosed with SCLC 
because allelic loss in discrete regions of 3p, including 3p21.3, occur in the majority of normal 
bronchial epithelium that accompany SCLC tumours 132. Furthermore, paired RNA samples were 
not obtained, preventing confirmation that RBM5 was downregulated in this cohort. Without 
performing analyses that take into account both non-tumour and tumour DNA and RNA in a 
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sufficient number of samples, it cannot be determined if deletion of RBM5 is the mechanism of 
RBM5 downregulation in SCLC.  
Although there was a greater frequency of RBM5 deletions in the Slovakian SCLC cohort, 
compared to the HSN NSCLC cohort, it could not be determined whether this phenomenon was 
a characteristic of SCLC as a disease, or was a characteristic of this Slovakian cohort, 
specifically. Since LOH at 3p21.3, which may include the RBM5 gene, occurs more frequently in 
SCLC (>95%), compared to NSCLC (<70%), it is conceivable that the greater frequency of 
RBM5 deletions in SCLC was the result of the disease itself, and not the cohort 45,46,133. To 
confirm that the frequency of RBM5 deletions in SCLC tumours is consistent across multiple 
cohorts, RBM5 gene copy number must be examined in a number of SCLC cohorts. 
5.3 Smoking may contribute to deletion of RBM5 in patients diagnosed 
with NSCLC, especially in non-tumour tissue 
Since RBM5 deletions in non-tumour tissue occurred only in smokers, and these deletions were 
related to loss of expression, it suggests that RBM5 deletion is related to smoking, though 
statistical significance cannot be attributed to this observation since the sample size was too low. 
This smoking-related lesion may lead to loss of expression that contributes to NSCLC 
development, as per the sequential theory of lung cancer development 127. In this cohort, one-
quarter (15/60) of smokers diagnosed with NSCLC displayed RBM5 deletions in non-tumour 
tissue, indicating that smoking-induced RBM5 LOH may be an important mechanism of early 
RBM5 downregulation in a substantial number of smokers that develop NSCLC. 
In regards to RBM5 deletions in NSCLC tumour DNA, there was no relationship with smoking, 
but a larger never-smoker sample size was necessary to draw accurate conclusions. Since there 
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were only five samples with variable RBM5 copy numbers obtained from never-smokers, it could 
not be determined if the proportions of the different copy number events were representative of a 
broader non-smoking population. Since 40% (2/5) of never-smokers displayed RBM5 deletions 
in tumour DNA, and only 20% (12/60) of smokers displayed RBM5 deletions in tumour DNA, it 
was speculated that the data obtained from never-smokers was not typical. Based on the evidence 
presented in the literature, LOH at 3p21.3, which may include the RBM5 gene, is related to 
tobacco smoke exposure 133. As a consequence, it would not be anticipated that a greater 
proportion of never-smokers would develop a smoking-related lesion, in comparison to smokers.  
Similar to what was observed in the HSN cohort, there were not any significant differences in 
RBM5 copy number between never-smokers and smokers in the Slovakian cohort, suggesting 
that, once again, RBM5 copy number in tumours was not related to smoking. In this study, 
sample size was also a factor, as there were only eight never-smokers that were compared to 34 
smokers. Smokers and never-smokers demonstrated RBM5 deletions in 50% (17/34) and 63% 
(5/8) of tumours, respectively, suggesting that the loss of RBM5 may be a common characteristic 
of SCLC tumours that is not necessarily related to smoking, and is, instead, related to the disease 
itself.  
5.4 Exploring alternative methods of RBM5 downregulation 
Since RBM5 deletion only accounts for approximately one-fifth of RBM5 downregulation in 
tumours, other mechanisms of RBM5 downregulation must be explored. Based on what has been 
documented in the literature, mutations are not a likely mechanism of RBM5 downregulation 
13,42,134. As mentioned previously, promoter hypermethylation cannot be ruled out as a 
mechanism of RBM5 downregulation. A more thorough examination of DNA methylation of the 
RBM5 gene, including the promoter region, should be completed. This examination could be 
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completed using techniques such as bisulfite sequencing, high performance liquid 
chromatography – ultraviolet, or liquid chromatography coupled with tandem mass spectrometry 
135.  
The mechanisms by which other TSGs that map to the common 3p21.3 deletion region are 
downregulated in lung cancer, might provide insight into how RBM5 is also downregulated in 
lung cancer. One of the most commonly studied TSGs from the common 3p21.3 deletion region 
is RASSF1A 136. RASSF1A is downregulated in the majority of lung cancers, like RBM5. 
Furthermore, similar to RBM5, the RASSF1A gene is rarely mutated 39,136. The most common 
mechanism of RASSF1A downregulation is tumour-acquired promoter hypermethylation, 
occurring in approximately 90% of SCLCs and 50% of NSCLCs 87. As a secondary mechanism 
of RASSF1A downregulation, the loss of one allele can be achieved through LOH at 3p21.3 137. 
One study that examined mechanisms of RASSF1 inactivation in primary lung tumours found 
that RASSF1A was methylated in 72% of SCLCs and 34% of NSCLCs 138. In the NSCLC group, 
39% of samples demonstrated LOH at 3p21.3 and not methylation 138. The percentage of 
tumours showing both methylation and LOH at 3p21.3 was 70% and 27% for SCLC and NSCLC 
tumours, respectively 138. The results of the Agathanggelou et al. study show that both 
methylation and LOH at 3p21.3 are important mechanisms of RASSF1A downregulation in lung 
cancer. Other TSGs that map to the common 3p21.3 deletion region, such as SEMA3B and 
CACNA2D2, follow similar mechanisms of inactivation, suggesting that RBM5 downregulation 
in lung tumours is also influenced by both methylation and LOH 87. 
It is also possible that RBM5 is downregulated by deficiencies in transcriptional machinery 
responsible for regulating RBM5 expression. To date, there have not been any studies completed 
that have examined regulation at the promoter region, or regulation of transcriptional machinery. 
88 
 
Perhaps, if the RBM5 gene itself is not altered, there might be alterations in transcription factors 
or regulatory elements that bind to the RBM5 gene and regulate its expression. Given the recent 
studies implicating microRNAs in the downregulation of various TSGs, it is also possible that 
microRNAs might play a role in the downregulation of RBM5. In fact, one recent study 
demonstrated that RBM5 is a target of miR-483-5p in prostate cancer 139. The Yang et al. study 
demonstrated that miR-483-5p expression increased in prostate cancer cell lines and tissue 
samples, compared to normal cell lines and tissue samples, and negatively regulated RBM5, 
leading to a loss of RBM5 protein expression 139. It is, therefore, possible that microRNAs may 
also play a role in the regulation of RBM5 expression in lung cancer. 
5.5 Conclusion 
The purpose of this study was to determine if the significantly decreased levels of RBM5 
expression in the NSCLCs of smokers was related to RBM5 deletion. Deletion of RBM5 in non-
tumour DNA was related to loss of RBM5 expression at the mRNA level, but the same result 
was not observed in the NSCLC tumour DNA. Although RBM5 deletions were observed in a 
small percentage of tumours, the deletions did not occur frequently enough to account for the 
significant downregulation of RBM5 observed at the mRNA level. RBM5 is, therefore, 
downregulated by more than one mechanism. In the future, RBM5 deletions should be confirmed 
in the HSN cohort, and, alternative mechanisms of RBM5 downregulation, such as promoter 
hypermethylation, should be examined. 
In regards to tobacco smoke exposure, RBM5 deletions in non-tumour tissue were only observed 
in smokers, suggesting a possible relationship between RBM5 deletion and smoking. In the 
tumours, however, RBM5 deletion was observed in both smokers and never-smokers, suggesting 
that RBM5 deletion in NSCLC was not related to smoking. Similar results were observed in 
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SCLC tumours. This analysis, however, was complicated by the lack of available tissue 
specimens from never-smokers. In the future, deletion of RBM5 should be examined in a greater 
number of never-smokers in order to gain statistically meaningful insight into the relationship 
between RBM5 deletion and smoking. 
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Appendix 
A.1 Introduction 
It has previously been documented that RBM5 protein is downregulated in approximately 70% 
of NSCLCs 27,40. Since protein samples were obtained from patients in the HSN cohort, RBM5 
protein expression was examined for further confirmation that RBM5 was downregulated in 
NSCLC tumours. It was previously confirmed that RBM5 mRNA expression significantly 
decreased in tumours from the HSN cohort, and so it was anticipated that the protein expression 
would also be significantly decreased in tumours. Concerning the protein, the primary objective 
was to confirm that RBM5 protein was downregulated in NSCLC tumours. This was achieved by 
Western blot analysis of 132 patient samples, consisting of paired non-tumour and tumour 
protein from 60 patients diagnosed with ADC or SqCC, and six patients diagnosed with mixed 
NSCLC. Statistical analyses were carried out on the patients diagnosed with ADC and SqCC 
only. 
A.2 Materials and Methods 
A.2.1  Protein samples 
Protein was extracted from fresh frozen tissue as described previously, using the Qiagen Allprep 
DNA/RNA/Protein Mini kit (Qiagen, Mississauga, ON, Canada). Protein was quantified using 
the Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, U.S.A.). A total of 132 
samples consisting of paired non-tumour and tumour protein from 66 patients were used in this 
study. Of these 66 patients, 42 patients were diagnosed with ADC, 18 were diagnosed with 
SqCC, and six were diagnosed with mixed NSCLC.  
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A.2.2  Western Blot Analysis 
Protein samples were prepared by diluting 50 μg of protein in a 1:2 ratio with Western loading 
buffer consisting of 0.06 M Tris-HCL pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue, 
and 5% β-mercaptoethanol. Diluted samples were then heated for 5 minutes at 95°C. The protein 
samples and a Precision Plus Protein Ladder (Bio-Rad) were then loaded onto a polyacrylamide 
gel containing a 4% stacking gel (0.125 M Tris, 0.1% SDS, 4% acrylamide, 0.05% APS and 
TEMED) and a 7% resolving gel (0.375 M Tris, 0.4% SDS, 7% acrylamide, 0.1% APS and 
TEMED). Samples were electrophoresed in running buffer (0.025 M Tris, 0.19 M glycine and 
0.1% SDS) at 100 V for approximately 1.5 hours, until the 37 kDa marker was at the bottom of 
the resolving gel.  
Once electrophoresis was complete, the protein was then transferred onto a PVDF membrane 
(GE Health Care, Mississauga, ON, Canada) using a wet transfer apparatus containing transfer 
buffer (25 nM Tris, 192 mM glycine and 20% methanol) for 75 minutes at 350 mA. The transfer 
of the protein to the PVDF membrane was confirmed with Ponceau S (Bioshop). The PVDF 
membrane was subsequently rinsed twice with TBS-T (20 mM Tris, 0.5 M NaCl and 0.1% 
Tween-20), and then washed three times in TBS-T on a shaker at room temperature for 15 
minutes, 5 minutes and 5 minutes, respectively. The membrane was then blocked in 5% non-fat 
dry milk (Carnation Evaporated Milk, Smuckers, Markham, ON, Canada) diluted with TBS-T on 
a shaker for 45 minutes at room temperature. After blocking, the membrane was rinsed twice 
with TBS-T, and then washed with TBS-T three times on a shaker at room temperature for 15 
minutes, 5 minutes and 5 minutes, respectively. The membrane was then placed in plastic Kapak 
bag (Ampac, Cincinnati, OH, U.S.A.) containing 3% non-fat dry milk diluted in TBS-T with 
primary antibody. The antibodies used included rabbit anti-human-RBM5 LUCA-15 UK 
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(1:3500, non-commercially available) and rabbit anti-human β-Actin (ACTB) (1:10,000, NB600-
532, Novus Biologicals, Oakville, ON, Canada). The sealed Kapak bag containing the membrane 
and antibody was then placed at 4°C on a rotator overnight.  
Following the overnight incubation, the membrane was rinsed twice with TBS-T and washed 
three times in TBS-T on the shaker at room temperature for 15 minutes, 5 minutes and 5 
minutes, respectively. The membrane was then placed in a 3% non-fat dry milk solution diluted 
with TBS-T, containing a goat anti-rabbit HRP-conjugated secondary antibody (1:10,000, sc-
2004, Santa Cruz Biotechnologies Inc., Dallas, TX, U.S.A.). This solution was placed on a 
shaker for 1 hour at room temperature. Detection of antibodies was achieved using Amersham 
ECL Western Blotting Detection Reagents (GE Healthcare, Mississauga, ON, Canada) and 
Amersham Hyperfilm ECL (GE Healthcare). Quantification of RBM5 expression was performed 
using AlphaEase FC software (Alpha Innotech). All RBM5 expression values were normalized 
to ACTB. Duplicate Western blots were performed for each patient sample. 
A.2.3  Peptide Block 
A peptide block was used to examine LUCA-15 UK antibody specificity. Three peptides were 
used in the initial peptide block experiments: UK peptide, LSLN peptide and LSLC peptide. The 
location of the peptides on the full-length RBM5 protein is displayed in Figure A1. Peptides 
were diluted to 0.5 μg/μl in 1X PBS (Life Technologies, Burlington, ON, Canada) and then 
stored at -20°C. For the peptide block, the anti-human RBM5 LUCA-15 UK antibody was 
combined with 30 μg of peptide in a microfuge tube containing 1X PBS (Life Technologies), 
with a total volume of 500 μl. The microfuge tubes containing the antibody and the peptide were 
incubated at 4°C overnight, on a rotator. Prior to incubating the PVDF membranes in primary 
antibody, the antibody and peptide solution was combined with TBS-T, making a total volume of 
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6 ml, and mixed with 0.18 g non-fat dry milk powder to achieve a 3% milk solution. For the 
peptide block, 30 μg of peptide were used because concentrations of 5 μg/ml (in the final milk 
solution) were recommended by antibody manufacturers in online peptide blocking protocols 
(i.e. AnaSpec and Neuromics). PVDF membranes were then placed in a Kapak bag and 
combined with antibody, as described in A.2.2. After performing the peptide block experiment, it 
was noticed that the LSLC peptide, while not specifically blocking the LUCA-15 UK antibody, 
reduced the background associated with the LUCA-15 UK antibody. Because of this, a peptide 
block was performed prior to using the LUCA-15 UK antibody when analysing RBM5 protein 
expression in patient samples, using the method described above. 
 
Figure A1 Location of RBM5 peptides on full-length RBM5 protein. This schematic diagram 
was constructed to demonstrate the regions of full-length RBM5 protein from which UK peptide, 
LSLN peptide and LSLC peptide originated. 
 
MGSDKRVSRTERSGRYGSIIDRDDRDERESRSRRRDSDYKRSSDDRRG
DRYDDYRDYDSPERERERRNSDRSEDGYHSDGDYGEHDYRHDISDERE
SKTIMLRGLPITITESDIREMMESFEGPQPADVRLMKRKTGVSRGFAFVE
FYHLQDATSWMEANQKKLVIQGKHIAMHYSNPRPKFEDWLCNKCCLN
NFRKRLKCFRCGADKFDSEQEVPPGTTESVQSVDYYCDTIILRNIAPHTV
VDSIMTALSPYASLAVNNIRLIKDKQTQQNRGFAFVQLSSAMDASQLLQ
ILQSLHPPLKIDGKTIGVDFAKSARKDLVLSDGNRVSAFSVASTAIAAAQ
WSSTQSQSGEGGSVDYSYLQPGQDGYAQYAQYSQDYQQFYQQQAGG
LESDASSASGTAVTTTSAAVVSQSPQLYNQTSNPPGSPTEEAQPSTSTST
QAPAASPTGVVPGTKYAVPDTSTYQYDESSGYYYDPTTGLYYDPNSQYY
YNSLTQQYLYWDGEKETYVPAAESSSHQQSGLPPAKEGKEKKEKPKSKT
AQQIAKDMERWAKSLNKQKENFKNSFQPVNSLREEERRESAAADAGF
ALFEKKGALAERQQLIPELVRNGDEENPLKRGLVAAYSGDSDNEEELVER
LESEEEKLADWKKMACLLCRRQFPNKDALVRHQQLSDLHKQNMDIYR
RSRLSEQELEALELREREMKYRDRAAERREKYGIPEPPEPKRKKQFDAGT
VNYEQPTKDGIDHSNIGNKMLQAMGWREGSGLGRKCQGITAPIEAQ
VRLKGAGLGAKGSAYGLSGADSYKDAVRKAMFARFTEME
UK peptide (amino acids 1-15)
LSLN peptide (amino acids 67-83)
LSLC peptide (amino acids 735-748)
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A.3 Results 
A.3.1  Two RBM5 bands with reciprocal expression were observed in non-
tumour and tumour protein 
In initial Western blots with patient protein samples, one RBM5 protein band around 113 kDa 
was anticipated, as only one RBM5 band was previously observed in various cell lines and in 
primary breast samples using the LUCA-15 UK antibody 16,37,140,141. Unexpectedly, two 
prominent bands at approximately 113 kDa (RBM5) and 124 kDa, were observed. Expression 
was reciprocal in nature, when comparing non-tumour and tumour protein (Figure A2).  
Although the LUCA-15 UK antibody has been shown to detect a number of non-specific bands, 
a non-specific band at 124 kDa has not been observed in various cell lines or in breast tissue 
16,37,140. Interestingly, expression of the 113 kDa and 124 kDa bands were reciprocal in nature 
when comparing non-tumour and tumour tissue. In non-tumour tissue, the upper band was more 
highly expressed than the lower band, while, in tumour tissue, the lower band was more highly 
expressed than the upper band. The reciprocity of the two bands, and the fact that a non-specific 
band at 124 kDa has never been observed, suggested that the 124 kDa band was a specific post-
translationally modified version of RBM5 protein that was specific to lung tissue. 
In order to determine if the upper band was specific, a peptide block was performed using three 
distinct peptides, each specific to a different segment of the full-length RBM5 protein. The UK 
peptide was the peptide that the LUCA-15 UK antibody was raised against, and consisted of the 
first 15 amino acids of the full-length RBM5 protein, while the LSLN and LSLC peptides were 
not specific targets of the LUCA-15 UK antibody, as they consisted of amino acids 67-83 and 
735-748, respectively. It was anticipated that blocking the LUCA-15 UK antibody with the UK 
peptide would result in elimination of specific RBM5 bands on the membrane, as the UK peptide 
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Figure A2 Western blots containing patient non-tumour and tumour samples that were 
probed with the LUCA-15 UK antibody. Western blot replicates containing patient non-
tumour and tumour protein probed with the LUCA-15 UK antibody, demonstrating the 113 kDa 
and 124 kDa bands. ACTB was used as the loading control for all patient samples. Upper panel: 
RBM5. Lower panel: ACTB. Red letters = mixed NSCLC samples that were not included in 
statistical analyses. 
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would saturate the antibody, preventing the antibody from binding to specific targets. 
Alternately, the non-specific LSLN and LSLC peptides were expected to eliminate non-specific 
binding on the membrane, allowing the antibody to bind more specifically to true RBM5 
proteins. Since it was suspected that the 124 kDa band was, in fact, a post-translationally 
modified version of the RBM5 protein, it was expected that both the 124 kDa and 113 kDa bands 
would not appear when blocking the antibody with the UK peptide, but remain unaffected when 
the antibody was blocked with the LSLN and LSLC peptides. Results of the peptide block are 
displayed in Figure A3. 
When using the LUCA-15 UK antibody on its own, both bands of interest were observed at 113 
kDa and 124 kDa, respectively, along with a number of other bands below 100 kDa (Figure A3 
A). As anticipated, when the LUCA-15 UK antibody was blocked with UK peptide, both 113 
kDa and 124 kDa bands disappeared, while non-specific bands below 100 kDa remained, with 
the exception of the band located at 40 kDa (Figure A3 B). The 40 kDa band was observed 
previously in Jurkat cells 37. The authors of the paper that previously identified the 40 kDa band 
stated that the protein did not correspond to any mRNA variants, and may, therefore, represent a 
proteolytic cleavage product derived from the full-length protein 37. Expression of the 40 kDa 
band was not analyzed in this study. After blocking with LSLN and LSLC peptides, both 113 
kDa and 124 kDa bands were visible once again (Figure A3 C and A3 D). Taking the results of 
the peptide blocks as a whole, it was concluded that the 124 kDa upper band was, indeed, RBM5 
protein, and hypothesized that it was post-translationally modified. It was also realized that the 
LSLC peptide reduced the background associated with the LUCA-15 UK antibody. As such, the  
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Figure A3 LUCA-15UK peptide block analyses. Four identical PVDF membranes containing 
the same protein samples were probed with (A) 1:3500 LUCA-15 UK, (B) 1:3500 LUCA-15 UK 
pre-incubated with 30 µg UK peptide, (C) 1:3500 LUCA-15 UK pre-incubated with 30 µg LSLN 
peptide, and (D) 1:3500 LUCA-15 UK pre-incubated with 30 µg LSLC peptide. NT26: non-
tumour lung tissue from patient 26; T26: tumour lung tissue from patient 26; BEAS-2B: lung cell 
line. Marker: Precision Plus Protein Ladder (Bio-Rad). Arrows indicated specific LUCA-15 UK 
bands that were blocked by the UK peptide. Dots indicate non-specific bands detected by the 
LUCA-15 UK peptide. 
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LUCA-15 UK antibody was pre-incubated with LSLC peptide  prior to use on PVDF membranes 
containing patient samples. 
Duplicate Western blots were performed with paired non-tumour and tumour protein samples 
from 60 patients, including 42 diagnosed with ADC and 18 diagnosed with SqCC, respectively. 
Expression of each RBM5 band was quantified by densitometry and normalized to ACTB 
expression. Expression of all RBM5 bands were quantified, and the average expression of each 
band was calculated for duplicate samples. Average normalized RBM5 expression values were 
then graphed. Outliers were identified using the Tukey method, and excluded prior to statistical 
analyses. The normalized RBM5 expression values in non-tumour and tumour data sets did not 
follow a normal distribution, as per the Shapiro-Wilk test, meaning that non-parametric analyses 
were ideal for subsequent statistical tests. Since the non-tumour and tumour samples were paired, 
the non-parametric Friedman test was used to determine if there was a statistically significant 
difference in mean expression of the various RBM5 bands in paired samples. Results are 
displayed in Figure A4. Combining the data from patients diagnosed with ADC and SqCC, it 
was clear that the reciprocal expression patterns of the RBM5 bands were conserved across the 
majority of patient samples (Figure A4 A). The upper band was significantly more expressed 
than the lower band in non-tumour tissue, while the lower band was significantly more expressed 
than the upper band in tumour tissue. Comparing non-tumour tissue to tumour tissue, the 
expression of the upper band significantly decreased in tumour tissue, while the expression of the 
lower band significantly increased in tumour tissue. Examining the patients diagnosed with ADC 
and SqCC separately, this expression pattern was conserved (Figure A4 B and A4 C). 
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Figure A4 Expression analyses of 113 kDa and 124 kDa RBM5 bands. A Freidman test was 
used to determine if there were significant differences in expression of 113 kDa (lower) and 124 
kDa (upper) bands in the non-tumour and tumour tissue of patients diagnosed with (A) NSCLC, 
(B) ADC, and (C) SqCC. *p<0.05, **p<0.01, ***p<0.001. NT = non-tumour, T = tumour. 
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A.3.2  Total RBM5 expression decreased in NSCLC tumours 
Since the original objective of this study was to determine if RBM5 protein was significantly 
reduced in NSCLC tumours, the difference in mean total RBM5 expression was compared 
between non-tumour and tumour tissue, taking the total expression of both of the 113 kDa and 
124 kDa RBM5 bands into account. For each patient sample, average normalized total 
expression values were calculated from the duplicate Western blots. Outliers were identified 
using the Tukey method, and excluded prior to statistical analyses. The average normalized total 
RBM5 expression values did not follow a normal distribution according to the Shapiro-Wilk test. 
Since the non-tumour and tumour samples were obtained from the same patients, the paired 
Wilcoxon signed-rank test was used to determine if the difference in mean normalized total 
RBM5 expression was significant between non-tumour and tumour tissue. As expected, RBM5 
expression was significantly decreased in NSCLC (Figure A5 A). Separating ADC and SqCC, 
total RBM5 expression significantly decreased in ADC tumours, compared to normal adjacent 
lung tissue (Figure A5 B). Total RBM5 expression in SqCC tumours, however, was not 
significantly decreased (Figure A5 C). 
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Figure A5 Expression analyses of total RBM5 protein expression.  A Wilcoxon signed-rank 
test was used to examine significant differences in the mean total RBM5 expression values 
between non-tumour and tumour tissue in patients diagnosed with (A) NSCLC, (B) ADC, and 
(C) SqCC. ***p<0.001. 
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A.4 Discussion 
Since it was confirmed that RBM5 mRNA was significantly downregulated in NSCLC tumours, 
and the paired protein samples were available from the HSN cohort, it was possible to confirm 
the extent of RBM5 downregulation in NSCLC. Concerning total RBM5 protein expression, it 
was confirmed that RBM5 expression was significantly downregulated in NSCLC tumours, 
especially in ADC tumours, compared to adjacent normal lung tissue. Interestingly, the LUCA-
15 UK antibody detected a specific RBM5 protein at 124 kDa that had not previously been 
observed in other studies, in addition to the expected RBM5 protein observed at 113 kDa. The 
upper band was thought to be a post-translationally modified RBM5 protein that is specific to 
lung tissue. The expression of the 113 kDa and 124 kDa bands were reciprocal in nature, with 
the upper band being more highly expressed in the non-tumour tissue, and the lower band being 
more highly expressed in the tumour tissue. The reciprocity of the two specific RBM5 proteins 
alluded to a novel mechanism of RBM5 protein regulation in lung tissue. 
After all of the HSN NSCLC protein samples were analysed, a Western blot that was performed 
previously in the Sutherland Lab, using the LUCA-15 UK antibody, was examined to see if the 
124 kDa band was present in patients diagnosed with SCLC. The non-tumour and SCLC tumour 
tissue samples were obtained from the Ontario Tumour Bank. Paired non-tumour and tumour 
samples were received from two patients from Hamilton and Ottawa, whereas only tumour 
sample was obtained from one patient from Kingston. Looking at Figure A6, the 124 kDa RBM5 
band appeared in the Hamilton non-tumour sample, and appeared faintly in the Ottawa non-
tumour sample. In regards to the tumour samples, the 124 kDa band did not appear in any of the 
tumour protein samples. This result confirmed that the presence of the 124 kDa band was not 
limited to the HSN primary tissue specimens. 
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Figure A6 Confirmation of 113 kDa and 124 kDa RBM5 bands in Western blots from 
patient samples not included within the HSN cohort. A single Western blot containing 
Ontario Tumour Bank SCLC protein, and adjacent non-tumour protein, was probed with LUCA-
15 UK antibody (upper panel). ACTB was used as the loading control (lower panel). Arrows 
indicate the 113 kDa and 124 kDa RBM5 bands, respectively. 
It was hypothesized that the 124 kDa RBM5 protein was a version of RBM5 that had undergone 
extensive post-translational modification. Phosphorylation of RBM5 protein has been observed 
previously, but the change in molecular weight was only 5 kDa, approximately 17. The difference 
of 5 kDa already suggests extensive phosphorylation, as the addition of only one phosporyl 
group is expected to alter the molecular weight of a protein by 80 Da 142. The fact that a 
difference of approximately 11 kDa was observed suggests that, if RBM5 is post-translationally 
modified, the amount of modification is extensive. Using online resources, such as PhospoSite 
Plus®, that report experimentally observed post-translational modification to amino acid residues, 
we found that, in addition to phosphorylation, the RBM5 protein can also undergo acetylation, 
methylation and sumoylation 143. Looking at the RBM5 protein sequence, it also appears as 
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though RBM5 contains both myristoylation and glycosylation sequence motifs, however, neither 
of these post-translational modifications have been proven experimentally. According to a 
review of common post-translational modifications, modifications including myristoylation, 
acetylation, methylation and glycosylation are only expected to alter the protein molecular 
weight by 210 Da, 42 Da, 14 Da and >800 Da, respectively 144. Sumoylation, on the other hand, 
involves the covalent attachment of a SUMO protein, which can alter the molecular weight by 
approximately 15 kDa 145. 
In order to confirm or disprove the presence of any of these post-translational modifications, it 
would be necessary to treat protein lysates with enzymes or chemicals that would remove the 
various modifications, and then perform a Western blot analysis of the protein samples. If the 
position of the upper band shifts downward after specific treatments, and after being probed with 
LUCA-15 UK, we can determine which modifications are present. Sumoylated proteins can be 
detected by isolating RBM5 protein by immunoprecipitation, performing a Western blot 
containing the immunoprecipitated protein sample, and then probing with a SUMO antibody 146. 
Performing these experiments would be the next step in determining which modifications are 
present. Pinpointing which modifications are present may provide functional information 
regarding novel RBM5 regulation in normal and tumour lung tissue. 
A.5 Conclusion 
It was previously confirmed that RBM5 mRNA was significantly downregulated in the NSCLC 
tumours of the HSN cohort. To confirm the extent of RBM5 downregulation in this cohort, 
RBM5 expression was examined in non-tumour and tumour protein. As expected, RBM5 protein 
was significantly downregulated in NSCLC tumours. What was unexpected, however, was the 
presence of two RBM5 proteins with reciprocal expression in non-tumour and tumour tissue, 
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believed to be the result of post-translational modification of RBM5 protein. Further analyses 
must be completed in order to confirm which modifications are present, and how these 
modifications impact the regulation of RBM5 protein in lung tumours. 
 
